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Everything will be okay in the end.  
If it’s not okay, it’s not the end. 
 
(Fernando Sabino)  
  
  
ABSTRACT 
Both white and brown fat are highly vascularized tissues and vascular functions in adipose tissues 
remain largely unknown. In this thesis work, we aimed to study blood vessels in modulation of 
adipose tissue functions under physiological conditions. To achieve these goals, we have used 
genetic mouse models in combination with pharmacological approaches as powerful tools to 
investigate adipose vascularization in modulation of adipose tissue functions and metabolism. We 
have developed unique in vitro and in vivo methods and techniques to functionally and 
mechanistically address the interactions between endothelial cells (ECs) and adipocytes (ACs). 
These novel methods and findings may potentially pave new avenues for development of 
therapeutics for treatment of obesity and metabolic diseases by targeting the adipose vasculature. 
In paper I, we describe novel methods to induce browning and angiogenic phenotypes in white 
adipose tissues (WAT) by exposing mice to cold ambient temperature (4°C). We have also 
defined methodologies to measure basal and non-shivering thermogenesis-related metabolism in 
mice. Several immunohistological methods that are coupled to confocal microscopy analysis were 
established to accurately quantify expression of gene products that are associated with 
thermogenesis and angiogenesis. These model systems and methodologies have provided a 
fundamental basis for subsequent projects within and outside our laboratory to study adipogenesis 
and metabolism. With the available methods developed in paper I, in paper II we have studied the 
age-related vascular effects in modulation of fat mass, AC functions, blood lipid profiles and 
insulin sensitivity. Notably, Vegf expression levels in various WATs underwent continuous 
changes in different age populations. Anti-VEGF and anti-VEGFR2 treatment showed marked 
variations of vascular regression, with middle-aged mice exhibiting modest sensitivity. 
Interestingly, anti-VEGF treatment produced opposing effects on WAT AC sizes in different age 
populations and affected vascular density and AC sizes in brown adipose tissue (BAT). 
Consistent with changes of vasculatures and AC sizes, anti-VEGF treatment significantly 
increased insulin sensitivity in all groups, except for a rather modest improvement of insulin 
sensitivity in the middle-aged group. Similar to healthy mice, anti-VEGF treatment substantially 
improved insulin sensitivity in obese mice on a high fat diet. Our findings demonstrate that 
adipose vasculatures show differential responses to anti-VEGF treatment in various age 
populations and have therapeutic implications for treatment of obesity and diabetes with anti-
VEGF-based drugs. In paper III, we studied the paracrine regulation of AC functions by 
angiogenic ECs following cold- or pharmacologically induced adrenergic activation. We have 
found that ECs play an essential role in modulating AC functions during WAT browning. This 
paracrine effect is mediated by EC-derived PDGF-CC, which acts on progenitor cells to induce 
differentiation into ACs. Deletion of the Pdgfc gene in mice or blocking of PDGFR largely 
impairs the paracrine regulation of AC functions during WAT browning. In paper IV, we have 
developed an effective and reliable lymphangiogenesis assay that allows us to study the 
lymphangiogenic capacity of various factors in the absence of pre-existing lymphatics and other 
angiogenic stimuli. We took advantage of the avascular nature of the cornea to study the 
lymphangiogenic effect of any given factor or combination of factors. To this end, we have tested 
several angiogenic factors that are commonly present in adipose tissues and quantitatively studied 
corneal lymphangiogenesis.  
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1 INTRODUCTION 
1.1 OBESITY, METABOLIC DISORDERS AND THE ADIPOSE TISSUE 
During the past decades, obesity has developed into an epidemic affecting millions of people 
worldwide. The number of obese individuals has nearly doubled since 1980. According to the 
World Health Organization, more than 1.4 billion adults are currently overweight and 500 
million are clinically obese
1
. Obesity is diagnosed at a body mass index (BMI) ≥ 30 and it is 
characterized by increased lipid storage and expanded adipose tissue mass
1,2
. This condition 
affects multiple systems in the human body and constitutes a considerable risk factor for the 
development of severe and often fatal complications such as type 2 diabetes (T2D), coronary 
heart disease, hypertension, fatty liver disease, stroke, obstructive sleep apnea, dementia as 
well as certain types of cancer
2–4
. Obesity-related comorbidities globally account for the 
majority of deaths. In fact, obesity-related disorders are expected to dramatically affect 
longevity and a study has projected a potential decline in human life expectancy by the year 
2020 for the first time following a steady increase
2–4
. 
1.1.1 Insulin sensitivity, hyperglycemia and Type 2 diabetes 
The vast majority of diabetes cases worldwide can be attributed to non-insulin-dependent 
type 2 diabetes (T2D) mellitus
5
. This disease leads almost inevitably to macro- and 
microvascular complications often shortening the lifespan of the affected individual
5,6
. 
Symptoms of T2D include increased thirst, frequent urination, blurred vision, and impaired 
wound healing. Apart from these symptoms, the diagnostic criteria for T2D include a fasting 
blood glucose level of 126 mg/dl or higher. Additionally, an oral glucose tolerance test 
(OGTT) can be performed by administering a glucose load equivalent to 75 g anhydrous 
glucose. If the blood sugar level reaches 200 mg/dl or more two hours after this glucose 
challenge, T2D is diagnosed
5,7,8
. To evaluate chronic blood sugar levels (glycemia), a so-
called A1C test can be performed. This test is named after hemoglobin A1C, a glycosylated 
form of hemoglobin. As hemoglobin is the oxygen-transport protein in erythrocytes, which 
typically have a turnover rate of 3 months, this blood test is used to assess the average blood 
glucose level over a longer period of time. This test can also be employed to identify 
individuals that are at high risk for developing T2D but do not yet meet the diagnostic 
criteria
5,9,10
. While genetic predisposition is involved in the development of T2D, 
environmental factors such as lifestyle and overeating play a pivotal role in the pathogenesis 
of this disease
5,11
. 
In the healthy individual, glycemia is tightly controlled via insulin production and secretion 
by pancreatic beta (β) cells in the Islets of Langerhans12. Insulin is synthesized as a pro-
hormone in the endoplasmic reticulum and undergoes extensive posttranslational 
modifications as it is processed by proteases in the Golgi apparatus. The biologically active 
form of the insulin hormone is then packed into secretory vesicles
13–15
. Postprandial 
elevations of blood glucose promote release of insulin from the pancreas. The secretion of 
insulin is a biphasic process: In the early phase, preformed, stored insulin from the so-called 
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“readily-released pool (RRP)” is rapidly secreted. Once the RRP is depleted, in a second 
phase, a slower release of insulin which has been stored in secretory granules mobilized from 
the “reserve pool” is observed13,14,16. As a consequence of insulin secretion, glucose is taken 
up by peripheral insulin-sensitive organs such as liver, skeletal muscle and adipose tissue to 
restore normal blood glucose levels (normoglycemia). Apart from this direct mechanism, 
insulin promotes hepatic glycogenesis while inhibiting pancreatic secretion of the catabolic 
enzyme glucagon thereby preventing glycogenolysis and gluconeogenesis in the liver
15
. 
Together, these effects of insulin counteract postprandial hyperglycemia by regulating 
glucose homoeostasis.  
Insulin-stimulated glucose uptake into peripheral tissues is mediated by glucose transporters 
(GLUT). Among these transporters, GLUT4 is responsible for glucose uptake in skeletal 
muscle and adipose tissue
12,17,18
. Under basal, unstimulated conditions, GLUT4 is sequestered 
in vesicles in an intracellular pool (Fig. 1).  
 
Figure 1: Effects of postprandial insulin secretion. Secreted insulin binds to the insulin receptor expressed on ACs, 
skeletal muscle cells and hepatocytes and triggers an intracellular signaling cascade. This leads to PI3K/Akt-dependent 
phosphorylation of target molecules resulting in trafficking of GSV and insertion of the glucose transporter GLUT4 into 
the plasma membrane enabling glucose uptake from the bloodstream into the cell. Furthermore, insulin signaling results 
in the inhibition of gluconeogenesis and lipolysis whereas synthesis of FA, glycogen and proteins is stimulated.  
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Insulin secretion and binding to its receptor triggers vesicle trafficking via the 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway causing GLUT storage vesicles 
(GSV) to fuse with the plasma membrane resulting in relocation of GLUT4 to the cell 
surface
19–21
. Glucose molecules can then enter the cell by facilitated diffusion along the 
concentration gradient and are removed from the bloodstream thereby restoring 
normoglycemia
19,21,22
.  
Insulin action is modulated by a number of hormones, inflammatory cytokines and 
metabolites such as free fatty acids (FFAs) originating from the adipose tissue. Hypertrophic 
adipocytes (ACs) exhibit lower sensitivity to the lipolysis-suppressing effect of insulin 
thereby contributing to increases in circulating FFA and glycerol levels. Circulating FFAs 
and glycerol confer hepatic as well as skeletal muscle insulin resistance
23,24
. Therefore, 
obesity is often associated with insulin resistance. In insulin resistant individuals, liver, 
skeletal muscle and adipose tissue lose their ability to respond efficiently to insulin leading to 
reduced uptake of glucose from the bloodstream compared to healthy individuals. 
Additionally, postprandial insulin secretion fails to suppress hepatic gluconeogenesis and 
glycogenolysis thus further aggravating hyperglycemia
5,7,12
. Insulin resistance is often seen in 
obese patients that do not yet meet the diagnostic criteria for T2D and can usually be 
improved by lifestyle interventions such as exercise and weight loss
5
. Persistent insulin 
resistance will eventually cause pancreatic β cells to increase insulin production and secretion 
to compensate for the diminished responsiveness of target cells and organs to the hormone. 
Hyperinsulinemia, excess levels of circulating insulin, is therefore frequently seen at early 
stages of T2D
8,25,26
. Recently, this classical view of insulin resistance preceding 
hyperinsulinemia has been challenged by several studies indicating that insulin resistance 
may result from increased insulin levels. It remains to be elucidated in which order these 
conditions occur and it is possible that the pathogenesis of these events may vary between 
different individuals
26,27
. Nevertheless, untreated insulin resistance results in chronic 
hyperglycemia. Chronically elevated blood glucose levels can lower insulin secretion as 
glucose metabolism leads to the production of reactive oxygen species (ROS). There is 
evidence that large amounts of ROS in pancreatic β cells may cause damage to cellular 
components. Consequently, insulin production may be decreased due to β cell dysfunction 
and apoptosis
5,28–30
. 
Overall, T2D has devastating effects on the patient’s health. Acute complications include the 
life-threatening conditions ketoacidosis and coma. Long-term consequences of diabetes can 
be almost exclusively traced back to micro- and macrovascular complications as chronically 
elevated blood glucose levels eventually cause damage to blood vessels.
5,8,30
. Microvascular 
diseases arise due to damage to small blood vessels resulting in retinopathy, nephropathy and 
neuropathy. Macrovascular damage affects large vessels and arteries leading to 
cardiovascular complications including myocardial infarction and stroke
7,8,31,32
.  
It is noteworthy that excess adipose tissue mass itself does not automatically increase the risk 
for obesity-related co-morbidities. In fact, around 15 % of obese individuals do not develop 
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metabolic disorders
4,33
. Furthermore, recent studies indicate that fat distribution rather than 
fat mass per se determines the predisposition for developing obesity-related illnesses
4,34,35
. 
According to these studies, visceral fat mass reduction could markedly improve metabolic 
parameters such as glucose metabolism and insulin sensitivity while removal of subcutaneous 
(sc) adipose tissue was not associated with significant benefits
34–36
. Further indications that 
adipose mass cannot always be correlated with metabolic health are derived from 
lipodystrophy studies
4,23,37
. Lipodystrophy is a rare condition which manifests in partial or 
generalized absence of adipose tissues. This results in ectopic lipid deposition in non-adipose 
organs such as liver, skeletal muscle or pancreas causing dysfunction or apoptosis of cells in 
these organs
38
. As a result, patients suffer from metabolic dysfunctions such as insulin 
resistance, dyslipidemia and non-alcoholic fatty liver
23,37,39,40
. In affected individuals, absence 
of functional adipose tissue mass is associated with health risks similar to those seen in obese 
patients indicating that adipose tissue dysfunction is the major cause for the development of 
metabolic disorders
2–4,41
.  
1.1.2 The role of ageing in obesity and metabolic disorders 
Insulin sensitivity is frequently decreased in older individuals. Normal weight adults aged 55-
64 years display the same relative risk of developing T2D as younger, obese patients thus 
identifying ageing as an independent risk factor to develop insulin resistance
42–45
. Although 
the underlying mechanisms have not been fully elucidated yet, it is known that increasing 
visceral adiposity as well as accumulating senescent cells contribute to a pro-inflammatory 
cytokine profile in the blood. Elevated levels of inflammatory cytokines might hamper insulin 
signaling leading to insulin resistance
46
. Studies have also shown that ageing increases 
inducible nitric oxide synthase. This enzyme interferes with skeletal muscle insulin 
sensitivity through nitrosation of insulin receptor substrate (IRS)1 and other proteins involved 
in insulin signaling
47
. During the ageing process, considerable alterations of total fat mass as 
well as adipose tissue distribution occur. Several human and rodent studies indicate an 
increase in adipose tissue mass in middle-aged individuals compared to younger subjects. At 
old age however, stagnation and even decline of body weight, BMI and total fat mass have 
been described
48–53
. Moreover, with progressing age, adipose tissue is redistributed from 
subcutaneous locations to visceral depots and ectopic fat storage sites such as liver and 
muscle due a reduced lipid-storage capacity of ACs
50,54,55
. Both visceral adiposity and ectopic 
lipid deposition are correlated with metabolic disorders
39,56
. Obesity has been reported to 
accelerate ageing of adipose tissue and thereby promotes a rise in age-related diseases such as 
cardiovascular disease, cancer and neurodegenerative disorders in younger, obese subjects
57
. 
Senescence-like alterations have been identified in the adipose tissue of obese individuals 
including telomere dysfunction, increased oxidative stress and DNA damage
57,58
. 
In summary, obesity-related metabolic disorders primarily result from a chronic positive 
energy balance. Per definition, energy balance is composed of two components, namely 
energy intake and energy expenditure. In homeothermic animals that maintain a constant core 
body temperature independent from ambient temperature changes, energy expenditure is 
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determined by the basal metabolic rate, physical activity as well as facultative 
thermogenesis
59
. Energy intake and expenditure are at least in part regulated by the two 
distinct types of adipose tissues present in the body: white and brown adipose tissue.  
1.1.3 White adipose tissue  
White adipose tissue (WAT) is present in various species. However, its absolute mass greatly 
varies between different species but even within the same animal as seen in hibernating 
animals
60
. The major function of WAT is storage of excess energy in the form of triglycerides 
(TGs). In times of negative energy balance, e.g. during fasting or starvation, energy can be 
mobilized by lipolysis and becomes readily available to sustain bodily functions. Thereby, 
WAT is critical for maintaining whole-body energy homeostasis. In lean subjects, around 
20% of the total body weight is WAT and in obese individuals this number can reach up to 
50%
61
. This clearly illustrates that minor changes in AC functions can dramatically affect the 
whole body. WAT exists in multiple depots throughout the human body and there are marked 
morphological, functional and metabolic differences between subcutaneous and visceral 
white fat. WAT is characterized by structural heterogeneity and composed of a number of 
different cell types. While roughly 50% of cells in WAT are mature ACs, they are 
interspersed with ECs, macrophages, fibroblasts as well as preadipocytes forming the stromal 
vascular fraction
61–64
. White ACs typically contain a large, unilocular lipid droplet and have a 
low cytoplasmic content, the nucleus is located close to the plasma membrane and the 
periplasmic rim contains a few mitochondria
65,66
. The size of white ACs ranges from 25 – 
200 µm and can be adjusted depending on nutrient availability
61,64
. In times of positive 
energy balance, TGs accumulate within white ACs resulting in an increase of cell diameter. 
This presence of large, lipid-laden ACs is termed hypertrophy and constitutes the major 
mechanism of adipose tissue expansion in adults
3,67,68
. While the number of ACs is largely 
determined during childhood and adolescence, there are now indications that fat cell number 
may be increased by differentiation of committed adipose precursor cells. Thereby, chronic 
overeating may result in AC hyperplasia after existing ACs reach a critical maximum size 
and cannot deposit more lipids
3,4,67–69
. Interestingly, AC hyperplasia may be beneficial and 
protective for metabolic health as compared to hypertrophy. Several studies indicate that 
enlarged ACs are correlated with altered gene expression profiles, a pro-inflammatory 
phenotype and adipokine secretion patterns that are associated with obesity-related disorders 
such as insulin resistance
3,70–73
. As ACs undergo hypertrophy, their oxidative capacity as well 
as mitochondrial content decrease. When reaching a critical size, hypoxia-related stress is 
induced leading to cell death. Adipocyte apoptosis recruits macrophages that remove AC 
remnants and form characteristic “crown-like” structures. Consequently, obesity is associated 
with macrophage infiltration and a state of chronic low-grade inflammation
4,39,66,69,71,74–77
. 
Apart from its significant role in energy-storage, adipose tissue has fundamental endocrine 
functions. Over 600 biologically active factors are produced and secreted in WAT
3,78
. 
Adipose tissue-derived adipokines modulate a number of physiological events via autocrine, 
paracrine or endocrine (systemic) signaling. Apart from local effects within the adipose 
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tissue, such as inflammation or angiogenesis, adipokines regulate various systemic processes 
including appetite and satiety, insulin sensitivity, energy expenditure, blood pressure as well 
as endothelial cell functions
3,4,78–86
. The adipokine secretion pattern reflects the functionality 
of the adipose tissue and a shift towards a pro-inflammatory, diabetogenic profile indicates 
adipose tissue dysfunction
70,71,80,87
.  
Among the large number of adipokines, leptin is one of the most studied factors secreted by 
the adipose tissue. The peptide hormone is the product of the ob gene and almost exclusively 
expressed by differentiated, mature white ACs
88–91
. Leptin actions are mediated via the leptin 
receptor (LR) which is present in several tissues with highest levels in the hypothalamus. The 
major function of leptin is signaling of nutritional status, regulation of appetite and energy 
homeostasis. Circulating leptin signals to the central nervous system that energy repletion is 
achieved, inducing satiety
89,92,93
. A state of chronically decreased leptin levels result in 
hyperphagia and is involved in development or progression of obesity. Leptin deficiency in 
rodent models due to mutations in the ob gene or in the gene encoding LR increases food 
intake while decreasing energy expenditure, mimicking a starvation response
89,92–96
. Notably, 
a positive correlation between BMI or total body fat weight with circulating leptin levels has 
been shown. These findings suggest a dysregulation of leptin signaling rather than leptin 
production in humans as well as in rodent models of diet-induced obesity (DIO)
89,96,97
. 
Whereas obesity can be reversed by exogenous leptin administration to animals deficient in 
this hormone, effects are only moderate or completely absent in hyperleptinaemic subjects 
indicating leptin resistance
92,98,99
. 
1.1.4 Brown adipose tissue and non-shivering thermogenesis 
While WAT serves an energy repository, brown adipose tissue (BAT) is a thermoregulatory 
organ that dissipates stored energy to generate heat in a process termed non-shivering 
thermogenesis (NST). This process is only activated when the organism is in acute demand of 
heat (facultative thermogenesis). Increased NST capacity develops over time following 
chronic exposure to certain stimuli (adaptive thermogenesis)
100
. Adaptive thermogenesis 
consists of several steps including mitochondrial biogenesis, expression of mitochondrial and 
respiratory chain enzymes as well as expression of proteins that uncouple oxidative 
phosphorylation
101
. 
In mammals, BAT-related heat production is required and activated during the postnatal stage 
as well as in hibernating animals or during exposure to low ambient temperature. BAT-
thermogenesis is centrally regulated via hypothalamic pathways. Not only functional but also 
morphological differences are evident between WAT and BAT. The darker color of this 
thermoregulatory tissue is in part due to the dense vascularization of BAT. The tissue is 
innervated by sympathetic nerves that are distributed abundantly in BAT
102,103
. Brown ACs 
typically reach maximum diameters of 60 µm and are thereby markedly smaller in size 
compared to white ACs
64,103
. Each BAT AC contains multiple smaller lipid droplets and a 
large number of mitochondria expressing the BAT-specific uncoupling protein 1 (UCP1), 
which is located in the inner mitochondrial membrane
102–104
. This protein, also known as 
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thermogenin, uncouples oxidative phosphorylation from ATP synthesis and generates heat 
instead. This is achieved by dissipating the intermembrane proton gradient as UCP1 causes 
protons (H
+
) to leak into the mitochondrial matrix, thereby bypassing the ATP synthase
102–106
. 
BAT thermogenesis is activated by the release of the neurotransmitter norepinephrine (NE) 
from sympathetic nerve termini upon certain stimuli such as cold or food intake
107
. NE binds 
to β3 adrenergic receptors (Adrb3) expressed on brown ACs resulting in adenylate cyclase 
activation and subsequent cyclic AMP (cAMP) formation (Fig. 2).  
 
Figure 2: Adrenergic activation of beige and brown adipocytes. Activation of the β3 adrenergic receptor results in 
elevated intracellular cAMP levels leading to activation of protein kinase A (PKA). This kinase phosphorylates and 
activates the enzyme hormone sensitive lipase (HSL) catalyzing the last step in TG lipolysis. Free fatty acids (FFAs) are 
released and serve as a substrate for UCP1-dependent thermogenesis. TG-derived FFAs are further metabolized via β-
oxidation and enter the tricarboxylic acid cycle in the mitochondria; thereby, protons (H
+
) accumulate in the 
mitochondrial intermembrane space. UCP1 enables H
+
 to translocate back into the mitochondrial matrix and dissipate 
oxidative phosphorylation from ATP synthesis in favor of heat generation. Chronic adrenergic activation results in PKA-
dependent activation of PGC1α and subsequent upregulation of BAT-specific genes such as Ucp1, mitochondira 
biogenesis, BAT hyperplasia and browning of WAT. 
The second messenger cAMP, in turn, activates protein kinase A (PKA) which further 
mediates adrenergic signaling via phosphorylation of various target proteins. It has been 
shown that prolonged adrenergic activation results in mitochondrial biogenesis, BAT 
hyperplasia and elevated levels of UCP1
103,105
. Activated PKA is thereby involved in 
transmitting both acute and chronic effects of adrenergic stimulation: PKA phosphorylates 
the transcription factor CREB which activates transcription of the Ucp1 gene. Expression of 
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this gene is further stimulated by PKA-mediated activation of the p38 pathway
102,103,105
. The 
acute thermogenic effect however is mediated by PKA-induced lipolysis. Activated PKA 
phosphorylates perilipin, a protein covering TGs within the fat cell, which then dissociates 
from the lipids leaving them vulnerable for lipolytic attack. PKA further activates hormone-
sensitive lipase (HSL) which catalyzes the rate-limiting step in lipolysis of TGs
103,108–111
. 
FFAs liberated from TGs serve two purposes in subsequent UCP1 activity: they are directly 
involved in UCP1 activation but also serve as substrates for thermogenesis
103,112,113
.  
While the mechanism of fatty acid (FA)-induced UCP1 activation remains to be elucidated, 
the catabolic pathway of FAs is well established. After entering the mitochondria via the 
carnitine shuttle system, they undergo β-oxidation and the liberated acetyl-CoA moieties are 
further oxidized in the tricarboxylic acid cycle. This leads to the production of NADH and 
FADH, conveying electrons to the electron transport chain. During this process, H
+ 
are 
moved across the inner mitochondrial membrane into the intermembrane space creating a 
membrane potential. Via ATP synthase, H
+
 are channeled back into the mitochondrial matrix 
catalyzing ATP production. In brown fat cells however, this process is uncoupled by UCP1. 
This protein mediates a proton leak enabling H
+
 to return to the mitochondrial matrix 
independent of ATP production and instead generates heat
114–116
. BAT activity results in 
combustion of large amounts of lipids and glucose and has therefore been implicated in 
therapeutic intervention to counteract obesity
102–104,117,118
. 
In rodents, BAT is found in distinct anatomical locations. The most studied rodent BAT 
depot is located subcutaneously in the interscapular region and consists of two lobes
106,119,120
. 
Until recently, it was believed that BAT in humans is only present in neonates and does not 
exist in significant amounts in adults. However, 18[F]-2-fluorodeoxyglucose (FDG) positron 
emission tomography (PET) combined with computed tomography (CT) has revealed that 
BAT is present and active in adult humans. Human BAT is primarily located in the 
supraclavicular area, the neck region, paravertebral as well as in para-aortic and suprarenal 
locations
105,121–124
. However, amount and activity of human BAT seem to vary greatly 
between individuals. Even within the same subject, exogenous factors such as seasonal 
changes in ambient temperature affect the BAT status due to the plasticity of this 
tissue
102,107,122–124
. Interestingly, several studies point towards an inverse correlation between 
prevalence or activity of human BAT and obesity-related factors such as body fat percentage 
or BMI
102,125–127
. These findings suggest, that targeting BAT may indeed offer an attractive 
therapeutic approach to counteract obesity and obesity-related metabolic disorders. 
1.1.5 Adipogenesis and developmental origin of white and brown ACs 
In higher mammals, adipogenesis, the formation of adipose tissue, occurs during mid-
gestation. In two distinct phases, determination and differentiation, the adipogenic process 
gives rise to WAT and BAT (Fig. 3). While BAT is fully developed in the newborn in 
different species, substantial amounts of WAT are not detectable at birth in small rodents 
while it is present in human babies
60,128,129
.  
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Figure 3: Differentiation of white, beige and brown adipocytes. ACs are derived from mesenchymal stem cells. White 
and beige ACs originate from a Pax7
-
/Myf5
-
 progenitor while classic brown ACs share a common Pax7
+
/Myf5
+
 progenitor 
with skeletal muscle cells. Under appropriate conditions, these early progenitors become commited white, beige or 
brown AC precursor cells. During terminal differentiation, expression of PPARγ and C/EBPs determines both white and 
brown fat development. High expression levels of PRDM16 and subsequent expression of PGC1α and C/EBPβ drive the 
precursor cells towards beige or brown AC fate. Apart from de novo differentiation of beige ACs from a commited 
precursor, transdifferentiation of white to beige ACs has been described under various stimuli such as cold exposure. 
Beige ACs may respond in an adaptive manner to the energy status of an individual: in the absence of appropriate 
stimuli these cells remain quiescent and deposit energy. Under negative energy balance or upon other adrenergic 
stimuli, activated beige ACs dissipate stored energy.   
Adipogenesis of both white and brown fat cells is driven by the transcription factors 
peroxisome proliferator-activated receptor-γ (PPARγ) and CCAAT/enhancer-binding 
proteins (C/EBPs). There is compelling evidence that both cell types share mesodermal 
origin. Despite these similarities, it has recently been confirmed, that white and brown ACs 
are derived from distinct precursor cells. At an early stage of differentiation, mesenchymal 
stem cells give rise to a population of myogenic factor 5 (Myf5)-expressing cells and a subset 
of Myf5-negative cells
130–132
. Myf5
+
 cells are capable of differentiating into brown ACs 
whereas white ACs develop from the Myf5
-
 population
130,131
. In the presence of appropriate 
stimuli, these early adipose precursor cells (adipoblasts) become committed white and brown 
preadipocytes. At this stage, precursor cells retain their proliferative capacity and cell cycle 
arrest is required before committed preadipocytes differentiate into mature fat cells. 
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Differentiation occurs in a tightly controlled sequence of events: initial growth arrest, clonal 
expansion, early and late differentiation
131,133,134
. Growth arrest is mediated by the 
transcription factors PPARγ and C/EBPα which transactivate the expression of AC-specific 
genes. Morphologically, cells lose their fibroblast-like structure and adopt a spherical 
appearance; on a molecular level, expression of the preadipocyte marker Pref-1 is markedly 
reduced
131
. At later stages of terminal differentiation, lipolysis-associated genes, as well as 
genes involved in glucose metabolism and de novo-lipogenesis are expressed and cells 
accumulate lipids to become mature ACs
60,128,131,133–136
. While PPARγ and C/EBPs play 
important roles in driving both white and brown fat development, there are a number of 
transcriptional components directing mesenchymal stem cells towards a brown AC 
fate
120,134,136–138
. Brown AC precursor cells transiently express Myf5 and Pax7 thereby sharing 
a developmental origin with skeletal muscle cells. A master regulator in the determination 
and differentiation of brown fat cells is the transcriptional coregulator PRD1-BF1-RIZ1 
homologous domain containing 16 (PRDM16) which inhibits the myogenic pathway in favor 
of brown fat differentiation
137–139. PRDM16 coactivates C/EBPβ thereby inducing expression 
of Pparγ and PPARγ coactivator 1α (Pgc1α). Additionally, PRDM16 directly interacts with 
PPARγ and PGC1α to further drive brown AC differentiation and activation137,139. PGC1α is 
a transcriptional coactivator and plays a central role in mitochondrial biogenesis in various 
tissues, in particular in highly metabolically active organs such as heart, kidney, brain, liver, 
skeletal muscle and BAT
140–142
. It is critically involved in AC cell fate decision by specifying 
the genes targeted by transcription factors such as PPARγ thus inducing brown AC 
differentiation. Unexpectedly, ablation of PGC1α does not abolish BAT development as its 
functional loss is most likely largely compensated by the actions of PGC1β143,144. However, 
cold exposure or adrenergic stimulation require and strongly induce PGC1α expression in 
BAT. Simultaneously, phosphorylation by p38 directly activates and stabilizes PGC1α. 
Together, this results in mitochondrial biogenesis as well as induction of mitochondrial and 
thermogenesis-related genes such as Ucp1 leading to enhanced uncoupling of respiration. 
Thereby, this transcriptional coactivator provides a direct link between external stimuli and 
adaptive thermogenesis
59,101,141,145–147
. Importantly, is has been shown that adenoviral delivery 
of PGC1α to human differentiated, white ACs in vitro as well as to murine WAT in vivo 
could induce expression of Ucp1 underlining the role of PGC1α in the acquisition of a brown 
AC-like phenotype
140,148
. 
1.1.6 WAT browning and beige/BRITE adipose tissue 
Besides classical white and brown fat cells, a third type of ACs has recently been 
identified
149
. While these cells resemble white ACs as they have very low basal expression of 
Ucp1, they share common biochemical features and thermogenic capacity with brown fat 
cells. Under appropriate stimulation, these cells bear the hallmarks of brown ACs
69,149–151
. As 
opposed to BAT which is present as a distinct depot in rodents in the interscapular, cervical, 
axillary and perirenal region, BRITE (brown-in-white) or beige ACs are interspersed within 
WAT, particularly in the inguinal depot
146,149
. Interestingly, external stimuli such as cold 
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exposure or adrenergic stimulation with the Adrb3-agonist CL316,243 (CL) results in 
increased Ucp1 expression of beige ACs and a browning phenotype of WAT
101,129,145,152–156
.  
Recent studies using transgenic mice have shown that PRDM16 plays a critical role in the 
induction of a thermogenic program during scWAT browning. PRDM16 is both necessary 
and sufficient for brown-like adipogenesis in WAT and has thereby been identified as a 
mediator of adaptive thermogenesis in this tissue
126,138,154,157,158
. Browning was not reported in 
visceral WAT in these mice, where considerably lower endogenous levels of PRDM16 were 
detected
157,159
. Interestingly, whole body energy expenditure was greatly elevated in 
transgenic mice expressing PRDM16 in scWAT that moreover exhibited resistance to DIO 
and improved glucose tolerance. On a transcriptional level, PRDM16 interacts with PPARγ 
and PGC1α, thereby coordinating repression of WAT-related genes while inducing BAT 
genes including thermogenic and mitochondrial genes (Fig. 2)
129,131,138,146,154,157,158. PGC1α is 
a master regulator of the thermogenic program of brown and beige ACs in particular in 
response to adrenergic stimulation induced by cold exposure or Adrb3-agonists
145,146
. Loss of 
this transcriptional coactivator dramatically reduces cold-induced thermogenic capacity in 
vivo while ectopic expression in WAT induces expression of Ucp1 and other BAT-specific 
genes
129,146,154
. 
Despite certain similarities with classical brown ACs, beige fat cells are derived from 
different precursor cells and are characterized by a distinct gene expression pattern
149–151
. 
Whereas BAT ACs are derived from a Myf5
+
 lineage, beige ACs originate from a Myf5
-
negative precursor
146,151
. To date, the origin of beige ACs has not been unraveled 
conclusively and there are two distinct hypotheses regarding the emergence of these cells in 
WAT depots
129,131,146,150,151,154,159
: (i) transdifferentiation and (ii) de novo differentiation. The 
transdifferentiation hypothesis suggests that most or all white ACs possess an inherent ability 
to adopt a brown-like phenotype under appropriate stimuli
69,131,154,160
. According to this 
theory, interconversion between white and brown-like fat cells may be bidirectional and 
could provide an adaptive mechanism to respond to the nutritional and energy status of the 
organism. In times of energy surplus, these cells might possess a white AC-like phenotype 
with energy-storing properties while they might undergo browning in case of a negative 
energy balance or adrenergic stimulation and dissipate stored energy
156,161
. However, the de 
novo differentiation hypothesis is supported by accumulating evidence that brown-like cells 
emerging in WAT originate from a distinct progenitor cell. This subpopulation of precursor 
cells differs from classical white preadipocytes by expressing the selective cell surface 
markers CD137 and TMEM26
151,153
. At a basal state, such as under thermoneutral conditions, 
these beige ACs may appear unilocular and feature low expression of thermogenic genes. 
Adrenergic stimulation will induce morphological alterations towards a multilocular lipid 
distribution. Simultaneously, the thermogenic gene program is induced, including expression 
of high levels of Ucp1, allowing beige ACs to switch from an energy-storing to an energy-
dissipating state
151
. At this writing, there is evidence supporting both hypotheses and it 
remains elusive whether transdifferentation, de novo differentiation of beige precursor cells, 
or a combination of both accounts for WAT browning under adrenergic stimulation. 
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There is accumulating evidence that – in contrast to BAT identified in human infants – the 
molecular signature of the BAT recently detected in adult humans resembles more closely 
murine beige than classical brown fat
151,162
. Indeed, it has been reported in multiple studies 
that PET-scans reveal a rather low quantity of thermogenically active BAT in adult humans. 
Stimulation by acute cold exposure could activate the tissue and substantially increase uptake 
of the glucose analog FDG
117,121–123,126,162,163
. Considerable variations in BAT activity were 
detected even within the same subject due to seasonal variations in ambient temperature
118
. 
1.1.7 Current treatment strategies for obesity and metabolic disorders 
As metabolic disorders such as T2D are in the majority of cases caused by overweight or 
obesity, therapeutic approaches aim primarily at lowering the patient’s body weight. Lifestyle 
interventions such as low-calorie diet or exercise regimes have proven very efficient in 
weight loss therapy. However, these approaches are only successful given compliance of the 
patient and long-term adherence to these interventions
164,165
. In order to be considered 
clinically meaningful and significantly improve metabolic health, body weight has to be 
reduced by at least 5 % within one year
164,165
. Importantly, to achieve and sustain significant 
body weight loss, patients usually have to rely on long-term drug treatment. Several anti-
obesity drugs have been withdrawn from the market due to serious long-term adverse effects 
that were not observed during trial periods prior to their approval
164–166
. For instance, 
sibutramine, an oral appetite suppressant, has been used in obesity treatment and showed 
efficacy for clinically significant weight loss. However, sibutramine has been withdrawn 
from the market in 2010 since the compound was associated with severe cardiovascular 
toxicity
166–171
. Similarly, the appetite suppressant rimonabant has been discontinued due to 
adverse effects on the central nervous system
166,170,172
. At this writing, orlistat (Xenical
®
) is 
the only anti-obesity drug approved by the Food and Drug Administration. The compound 
functions as a lipase inhibitor. Thus, uptake of dietary lipids is inhibited and they are secreted 
via the feces. However, the drug is associated with gastrointestinal side effects that can be 
improved when consuming a low-fat diet
164,166,169,173–175
. In terms of morbid obesity and 
related health risks, bariatric surgery is the most efficient weight loss approach resulting in a 
nearly 25 % reduction of overall mortality
165,176
. It is also the most effective way of treating 
T2D in morbidly obese subjects. However, this procedure is highly invasive and linked to 
risks associated with any major surgery
165
. This clearly demonstrates that there is an urgent 
need for the development of novel therapeutic approaches for obesity and associated 
disorders.  
1.1.8 Therapeutic implications of human BAT 
The finding, that adult humans possess a low but significant amount of BAT which responds 
to activation, has provided new hope for the development of novel anti-obesity drugs. Recent 
studies have identified a number of molecules, pharmacological and nutritional agents as well 
as secreted proteins that contribute to WAT browning
155
. Interestingly, human studies have 
detected 63 g of BAT in the supraclavicular-paracervical depot of one particular subject. In 
relation to the total body weight of an adult human, this amount of tissue seems almost 
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negligible. However, according to estimations, this small amount of human BAT may be 
sufficient to substantially increase the individual’s energy expenditure. There is evidence that 
cold-induced NST results in a 40% increase over basal energy expenditure
177,178
. Notably, the 
primary substrate for BAT-thermogenesis is FFAs and only a fraction of its metabolism can 
be attributed to glucose functioning as a substrate for BAT thermogenic activity. According 
to calculations, merely 2% of thermogenesis in fully activated BAT is fueled by glucose
179
. 
During acute cold exposure, the main energy source is the combustion of lipids stored within 
brown ACs themselves. Prolonged BAT activation however, results in rapid depletion of the 
BAT lipid-pool and requires mobilization of lipids from the periphery. Circulating FFAs 
derived from WAT lipolysis as well as gut chylomicrons and hepatic lipoproteins provide 
fuel for BAT thermogenesis
177,178,180
. Assuming full activation of the tissue, this may result in 
the consumption of energy equivalent to 4.1 kg of WAT per year
122,162
. Consequently, BAT 
activation or potential WAT browning in adult humans may have substantial benefits for 
metabolic health. 
1.1.7.1 Environmental influences and physiological stimuli 
Cold exposure  
Cold exposure is a classical, physiological activator of BAT and also functions potently in 
BAT recruitment
118,146,155,181
. Acute effects of cold exposure activate BAT while elevated 
Ucp1 expression, mitochondrial biogenesis and BAT hyperplasia are observed after chronic 
exposure. In addition to activation of classical BAT depots, chronic cold exposure also results 
in the emergence of beige ACs in WAT depots
103,118,145,182,183
. Cold-induced alterations in 
BAT activity have been shown to correlate negatively with body fat content in human 
subjects. A study exposing male subjects to controlled cold, has shown that both blood flow 
within BAT as well as metabolic activity of the tissue were greatly elevated
177
. The cold 
stimulus inducing BAT activation is received via thermo transient receptor potential (TRP)-
channels which are members of the TRP ion channel family. In particular TRPM8 and 
TRPA1 seem to be sensitive to low ambient temperatures. Activation of these receptors 
occurs at temperatures of 20 °C and below. Indeed, human studies have confirmed BAT 
activation when subjects are exposed to temperatures of this magnitude
118,184,185
. 
Diet-induced thermogenesis (DIT)         
Ingestion of a meal is followed by a thermogenic response consisting of two components. 
This thermic effect of food however, is generally rather small accounting for approximately 
10 % of total energy intake. The obligatory component is attributed to the energy required for 
absorption and digestion of food, as well as synthesis and storage of absorbed nutrients as fat, 
carbohydrates and proteins
186,187
. Additionally, the facultative component further increases 
postprandial energy expenditure. There is evidence from both rodent and human studies, that 
this DIT component is mediated by sympathetic activation and BAT activity
178,188,189
. 
However, further studies are required to confirm a potential link between BAT and DIT
178,190
. 
Excessive caloric intake as well as diet composition is thought to affect the magnitude of 
DIT. Both caffeine and capsaicin, the active substance of hot peppers, increase DIT 
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presumably involving sympathetic activation
188,191–193
. Capsaicin elicits its function via 
binding to TRPV1, a heat-sensing member of the TRP ion channel family
118,184,185
. 
Furthermore, macronutrient composition of the diet also influences the magnitude of DIT. 
High protein/high carbohydrate proportions appeared to result in greater energy expenditure 
24 hrs postprandial compared to meals with a high fat content. This increase in metabolic rate 
appeared to be mainly due to differences in DIT
194
. 
Exercise 
Several studies indicate that in addition to cold- and diet-induced thermogenesis, prolonged 
exercise can also activate BAT thermogenesis
155,195
. This observation seems counterintuitive 
in light of muscle-induced heat generation occurring during exercise. Nevertheless, 
sympathetic BAT activation as well as recruitment of UCP1-expressing ACs to WAT depots 
has been described upon physical activity
195
. Recently, Irisin, a skeletal muscle-derived 
secreted hormone, has been identified. Secretion of this myokine is elevated upon exercise 
stimulus in rodents and humans via Pgc1α expression. Irisin is a hormone derived from 
proteolytical processing of the Fndc5 gene product. In adipose tissue, Irisin stimulates Ucp1 
expression and induces scWAT browning via Pparγ upregulation. Even moderately increased 
Irisin levels mediate a marked increase in whole body energy expenditure, ameliorate glucose 
homeostasis, and protect from to obesity-induced insulin resistance
152
. Exogenous delivery of 
this myokine may have great therapeutic potential in obesity and diabetes treatment. 
1.1.7.2 Endogenous secreted factors  
The family of natriuretic peptides (NPs) consists of atrial NP (ANP), brain NP (BNP) and 
C-type NP. ANP and BNP are primarily released from the atria and ventricles and therefore 
termed cardiac NPs. Cardiac NPs regulate ion homeostasis, body water and excretion of 
sodium in the urine (natriuresis) in the body. In adipose tissue, NPs are involved in the 
regulation of lipolysis. Recent studies indicate a role of these peptides in BAT activation, 
WAT browning and regulation of thermogenic programs, thereby increasing whole body 
energy expenditure
156,196
. Another example of secreted factors that induce browning is 
Fibroblast Growth Factor 21. Under certain conditions such as cold exposure, this 
endocrine hormone is secreted by the adipose tissue and regulates scWAT browning in a 
PGC1α-dependent manner154.  
1.1.7.3 Thiazolidinediones/Glitzaones 
Compounds of the class of Thiazolidinediones (TZDs) are used in the treatment of T2D. 
They are potent insulin sensitizers and exert their anti-diabetic effect via activation of 
PPARs, particularly PPARγ. However, the mechanism through which TZDs such as 
rosiglitazone mediate WAT browning remains to be elucidated
155,197
. It has been suggested 
that the underlying mechanism may involve stabilization of the PRDM16 protein thereby 
increasing its half-life
198
. 
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1.1.7.4 Genetic models 
Besides a number of secreted factors, several genetic models with an altered phenotype of 
BAT or beige fat have been described. AC-specific expression of the transcription factor 
forkhead box C2 under the ap2 promoter leads to scWAT browning, increase in Ucp1 
expression, as well as protection from obesity and diet-induced insulin resistance
156,199
. 
Interestingly, due to a hierarchical order of sympathetic activation, most agents that have a 
browning effect on WAT also recruit classical BAT. To date, only four compounds out of 
the rather large amount of browning agents have been identified to selectively induce 
browning of WAT without parallel BAT activation
156
. 
1.2 VASCULAR FUNCTIONS IN THE ADIPOSE TISSUE 
1.2.1 Angiogenesis and Vascular endothelial growth factor (VEGF) 
In the body of vertebrates, blood and lymphatic vessels play a crucial role in modulating a 
variety of physiological and pathological processes. Both systems are interconnected via 
the thoracic duct draining lymph into the blood circulation
200
. Angiogenic growth of 
lymphatic and blood vessels involves several tightly regulated steps including proliferation 
and migration of progenitor cells as well as tube formation and vessel maturation
200
. 
Hemangiogenesis, which will be referred to as angiogenesis in the following, is the growth 
of blood vessels by sprouting from pre-existing vessels. Sprouting angiogenesis stands in 
contrast to vasculogenesis, which describes the de novo formation of ECs by differentiation 
from committed mesodermal precursors
201–203
. Both vasculogenesis and angiogenesis are 
essential and rate-limiting during development and they are coordinated by a delicate 
interplay of various signaling molecules
201,204
. In growing tissues and organs, major blood 
vessels such as arteries and veins expand through remodeling and circumferential growth, 
while capillaries, microvessels that mediate gas and nutrient exchange, form networks via 
angiogenesis
200
. This occurs not only during embryogenesis and early development but also 
in the adult organism where angiogenesis plays a role in the female menstrual cycle, wound 
healing, pathogenesis of many diseases as well as adipose tissue expansion
200,202,205
. 
Disruptions and dysregulation of vessel growth can have detrimental consequences and 
both excessive as well as insufficient angiogenesis contribute to the pathogenesis of a 
number of disorders such as cancer, ischemia, atherosclerosis, neurodegeneration, obesity 
and T2D
63,202,206
. On a mechanistic level, angiogenic blood vessel growth is a multistep 
process initiated by a shift in the balance of pro- and anti-angiogenic factor expression. The 
signaling tissue secretes pro-angiogenic factors such as VEGFA which binds to VEGF 
receptor 2 (VEGFR2) expressed on ECs
207
. Upon ligand binding to this tyrosine kinase 
receptor, ECs are activated. VEGF-stimulated ECs release matrix metalloproteases leading 
to degradation of the basement membrane and extracellular matrix (ECM) consisting of 
laminins, heparan sulfate proteoglycans (HSPGs), collagen type IV and other 
components
208
. Thereby, stromal angiogenesis stimulators such as basic fibroblast growth 
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factor and platelet-derived growth factor (PDGF) that had been trapped by proteoglycans, 
are mobilized
200,207–209
. In response to VEGFR2 activation and ECM degradation, VEGFA 
functions as a chemoattractant and its spatial concentration gradient – along with other pro-
angiogenic factors – controls EC proliferation and migration towards the signaling 
tissue
200,204,208,210,211
. To create functional blood vessels, endothelial tube formation is 
required resulting in the development of a vascular lumen. Finally, increasing oxygen 
delivery decreases local Vegfa expression thereby promoting attenuation of angiogenesis
200
. 
Mural cells including pericytes (PCs) and vascular smooth muscle cells are recruited to the 
newly formed blood vessel providing stability. Deposition of ECM components in the 
basement membrane further promotes vessel maturation
200,206,207,212,213
. In pathological 
angiogenesis, vessel maturation is often abnormal resulting in unstable, disorganized and 
dysfunctional vascular networks
213
. 
Equivalent to hemangiogenesis, the term lymphangiogenesis describes the formation of 
new lymph vessels from pre-existing lymphatic vessels
200
. The lymphatic system plays an 
important role in interstitial fluid homeostasis, immunity as well as metabolism and has 
recently gained attention regarding metastatic spreading of tumor cells
214–216
. Although 
involving a different set of growth factors, receptors and signaling pathways, 
lymphangiogenesis follows a similar mechanism as hemangiogenesis including lymphatic 
EC (LEC) proliferation, sprouting, migration and tube formation
216
. While hemangio-
genesis is potently stimulated by VEGFA, lymphangiogenesis is mainly induced via the 
VEGFC/VEGFR3 signaling axis
200,217
. 
1.2.2 VEGFs and their receptors 
Both blood vessel angiogenesis and lymphangiogenesis are regulated by members of the 
VEGF family
210
. This group of growth factors comprises the following members (Fig. 4): 
VEGFA, VEGFB, VEGFC, VEGFD and placenta-derived growth factor (PlGF) 1 and 2 
sharing a common homology domain
218
. The existence of VEGFA splice variants further 
increases the functional diversity of this growth factor family
204,219,220
. The isoforms 
VEGFA145, VEGFA189 and VEGFA206 contain two heparin-binding domains and are 
consequently tightly bound to HSPGs. Isoforms that are sequestered in the ECM by HSPG 
binding can be mobilized via proteolysis. VEGFA165 and VEGFA121 are lacking one or both 
heparin-binding domains, respectively, and are therefore diffusible isoforms
218
. The major 
functions of VEGFA include proliferative effects on ECs and induction of vascular 
permeability. It also plays a role in EC survival, sprouting, migration and tube 
formation
210,219
. This factor is critically involved in both vessel development and 
maintenance
210
. VEGFA binds to VEGFR1, VEGFR2, neuropilin (NRP) 1 as well as 
NRP2. VEGFR2 has lower affinity for VEGFA compared to VEGFR1. However, VEGFR2 
seems to be of greater importance regarding VEGFA-mediated mitogenic effects and 
vascular permeability
219
. Vegfa expression is particularly critical during early development 
and even heterozygous deletion is embryonically lethal. Isoform studies indicate that 
VEGFA165 is the major effector of VEGF action
219,221
. The growth factor features highest 
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expression levels during developmental stages and expression decreases in most tissues 
during the postnatal period. 
 
Figure 4: VEGF family and their receptors. The members of the VEGF family and their receptors regulate angiogenesis, 
vasculogenesis and lymphangiogenesis. Ligand binding triggers the formation of receptors homo- or heterodimers 
resulting in their activation and intracellular signal transduction. In addition to membrane-bound receptors, this family 
comprises a soluble form of VEGFR1 (sVEGFR1), lacking the membrane-binding domain. 
Certain physiological processes and disease states requiring neovascularization may involve 
upregulation of Vegfa in the adult organism
222
. Low oxygen tension results in hypoxia 
which is an important trigger of Vegfa expression in several tissues as well as in tumors and 
other pathological settings. Oxygenation can be achieved through diffusion until the tissue 
reaches a particular size. However, oxygen diffusion limits are typically around 100 – 
200 µm and tissues exceeding this size require a functional vascular network to maintain 
physiologically appropriate oxygen levels
222,223
. Neovascularization is an adaptive response 
to tissue hypoxia and is observed in several pathological conditions such as coronary heart 
disease or tumor angiogenesis. The molecular mechanisms underlying hypoxia-induced 
angiogenesis have been studied extensively and are well understood. On a transcriptional 
level, responses to tissue hypoxia are mainly mediated by hypoxia inducible factors (HIFs) 
and in particular HIF-1, a heterodimer consisting of HIF-1α and the aryl hydrocarbon 
receptor nuclear translocator (Arnt)
222,224,225
. The HIF family of transcription factors 
regulates the expression of a number of genes involved in apoptosis, cell cycle, energy 
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metabolism and angiogenesis. The Vegfa gene is one of the HIF target genes that contains 
hypoxia response elements (HREs) in its 5’ and 3’ untranslated regions222,224,226. Under 
normoxia, the HIF-1α subunit is highly unstable. The protein is hydroxylated by prolyl 
hydroxylase domain-containing (PHD) enzymes using oxygen as a substrate, thereby 
initiating ubiquitination. Consequently, HIF-1α readily undergoes proteasomal degradation. 
Reductions in oxygen tension, however, result in attenuated hydroxylation of HIF-1α due to 
depletion of the PHD substrate and in this manner, hypoxia allows for intracellular HIF-1α 
accumulation
222,224,227
. Upon translocation of HIF-1α into the nucleus, where it forms a 
complex with Arnt and the coactivator protein CBP/p300, the transcriptional complex binds 
to HREs in the promoter and enhancer regions of target genes including Vegfa
222,224
. In 
addition to increasing Vegfa expression levels, hypoxic conditions have a stabilizing effect 
on Vegfa mRNA. Furthermore, there are a number of growth factors and cytokines such as 
PDGF-BB or transforming growth factor-β that upregulate Vegfa gene expression.   
While VEGFA is extensively studied, the role of VEGFB, which binds to VEGFR1 and 
NRP-1, is poorly understood. Studies indicate that the growth factor is dispensable for 
angiogenesis but critical for vascular maintenance and survival of vascular ECs, PCs, 
smooth muscle cells (SMCs), as well as vascular stem and progenitor cells
228
. VEGFB is 
produced by the heart, skeletal muscle and BAT, all of which are metabolically highly 
active tissues. Recently, it has been shown that VEGFB induces transendothelial transport 
of lipids via upregulation of fatty acid transport proteins and thereby coordinates the 
transport of lipids to peripheral energy-expending organs in a paracrine manner
229
. 
PlGF shows merely weak angiogenic activity. However, after heterodimer formation with 
VEGFA, this growth factor acts as a mitogenic factor on ECs and stimulates angiogenesis 
via signaling through VEGFR2
222
. 
VEGFC and VEGFD are ligands for VEGFR3 and are involved in lympangiogenesis. 
Similar to the fundamental role of VEGFA in hemangiogenesis, VEGFC governs the key 
events in the formation of new lymphatic vessels including sprouting, survival and 
proliferation of LECs. The lymphangiogenic activity of VEGFD however, is not crucial for 
lymphatic development. Although these ligands exert their actions mainly via binding to 
VEGFR3, they can also signal through VEGFR2
200,222
. 
1.2.3 Vascular endothelial growth factor receptors (VEGFRs) 
The three members of the VEGFRs are receptor tyrosine kinases (RTKs) consisting of 
seven extracellular immunoglobulin-like domains, a transmembrane regions and an 
intracellular tyrosine kinase domain
218
. In general, downstream signaling of RTKs is 
initiated by binding of a covalently linked ligand homo- or heterodimer
225,230
. Ligand 
binding results in dimerization of two receptor monomers, transautophosphorylation of 
intracellular tyrosine residues, and consequently RTK activation. Upon receptor activation, 
downstream signaling molecules are recruited and further transmission of the signal is 
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propagated through Src homology-2 (SH2) and phosphotyrosine binding (PTB) domain-
containing proteins
225,230
. Alternatively, the activated receptor can recruit adaptor proteins 
such as growth factor receptor-bound protein (Grb) 2 that mediate protein-protein 
interactions and thereby assembly of signaling complexes. Via this elaborate signaling 
cascade, extracellular ligand binding is translated into appropriate intracellular responses. 
VEGFR1 is expressed by hematopoietic stem cells, monocytes, macrophages as well as 
vascular ECs and binds VEGFA, VEGFB and PlGF (Fig. 5). This receptor exists both as a 
membrane-bound form and as a truncated, soluble splice variant (sVEGFR1).  
 
Figure 5: Downstream effects of VEGFR1-mediated signaling. VEGFR1 exists as a membrane-bound receptor and as a 
soluble splice variant (sVEGFR1) that can bind the ligands VEGFA, VEGFB and PlGF. Upon ligand binding, VEGFR1 
dimerizes resulting in transautophosphorylation of tyrosine residues. An intracellular signaling cascade is triggered 
regulating EC survival, proliferation, migration and vascular permeability. Importantly, tyrosine kinase activity of VEGFR1 
is rather weak and this receptor mainly functions as a decoy receptor preventing binding of VEGFA to VEGFR2. 
The precise function of this receptor has not been fully elucidated yet. Depending on 
developmental stage as well as cell type, VEGFR1 can exert different or even opposing 
functions. Deletion of the Vegfr1 gene is embryonically lethal and the receptor appears to 
act as a negative regulator of VEGFA during early development
225,230–232
. It has been 
proposed that VEGFR1 may function as decoy receptor by binding VEGFA with high 
affinity thereby preventing the interaction of this ligand with VEGFR2. There is compelling 
evidence that the soluble VEGFR1 isoform exerts an inhibitory effect on EC mitogenesis 
thus negatively regulating VEGFR2 and suppressing angiogenesis
218,225,231,233
. Membrane-
bound VEGFR1 interacts with a number of downstream signaling pathway components 
 20 
such as PI3K, phospholipase C (PLC)-γ, Src-homology domain 2-containig phosphatase 
(SHP2) and Grb2
234
.  
In contrast to VEGFR1, functions of VEGFR2 are much better understood. This receptor 
binds VEGFA, VEGFC and VEGFD. During adulthood, Vegfr2 is almost exclusively 
expressed in vascular ECs
232
. VEGFR2 is critically involved in developmental 
angiogenesis, physiological and pathological neovascularization. The affinity of VEGFA 
for this receptor is ten times lower compared to VEGFR1; nevertheless, VEGFR2 is the key 
regulator of mitogenesis, angiogenesis and vascular permeability
225,230,232
. Downstream 
signaling of VEGFR2 involves several major signaling cascades (Fig. 6): the PI3K-Akt 
pathway mediates EC survival and vessel permeability, the p38 MAP kinase pathway 
governs EC migration and the Ras-Raf-Mek-Erk pathway stimulates EC proliferation
225,235
.  
 
Figure 6: Downstream effects of VEGFR2-mediated signaling. VEGFR2 is almost exclusively expressed on vascular ECs 
and binds VEGFA with lower affinity than VEGFR1. However, VEGFR2 is the key regulator of EC mitogenesis, vascular 
permeability and angiogenesis. Upon ligand binding, VEGFR2 dimerizes and transautophosphorylation of intracellular 
tyrosine residues propagates growth factor signaling of this receptor tyrosine kinase. 
Expression of Vegfr3 is generally restricted to LECs and this receptor binds exclusively 
VEGFC and VEGFD. Although the downstream signaling pathways induced upon 
VEGFR3 activation remain to be unraveled, it has been suggested that signals are 
transduced via the PI3K-Akt and the Ras-Raf-Mek-Erk pathway. However, other signal 
transducers such as PLC-γ, SHP2, c-Jun N-terminal kinases (JNK) 1/2 and the transcription 
factors STAT3 and STAT5 might be involved in VEGFR3-mediated signaling 
(Fig. 7)
231,236–240
. 
  21 
 
Figure 7: Downstream effects of VEGFR3-mediated signaling. VEGFR3 is expressed on LECs and mediates lymphangio-
genesis. The receptor dimerizes upon binding of its ligands VEGFC and VEGFD leading to receptor activation. Intracellular 
signaling involves the PI3K/Akt and Erk pathways resulting in LEC survival, proliferation and migration. 
1.2.4 Platelet-derived growth factors (PDGFs) and their receptors 
The PDGF family consists of the ligands PDGFA, PDGFB, PDGFC and PDGFD as well as 
their tyrosine kinase receptors PDGFRα and PDGFRβ. These RTKs are structurally related 
to VEGFRs and consist of five extracellular immunoglobulin loops and an intracellular 
kinase domain
241,242
. PDGFs are mitogens for a number of mesenchymal cell types and bind 
as homo- or heterodimers to their respective receptors. Ligand binding induces receptor 
dimerization, autophosphorylation and activation
241,242
. The growth-factor mediated signals 
are further transduced through protein-protein interactions involving SH2 and PTB domains 
that provide docking sites for recruited effector proteins
241,243
. Several in vitro and in vivo 
studies have identified PDGF-AA, PDGF-AB, PDGF-BB and PDGF-CC as ligands for 
PDGFRα while PDGF-BB and PDGF-DD signal through PDGFRβ242. Downstream 
signaling of both receptors involves activation of the PI3K/Akt and MAPK signaling 
pathways as well as STAT signaling resulting in cell proliferation and survival thereby 
mediating the mitogenic effect of PDGFs
243,244
. It has been shown that PDGF-BB-mediated 
signaling induces growth of angiogenic vessels through stimulation of EC proliferation and 
survival via signaling through both PDGFRα and PDGFRβ245–247. Furthermore, PDGF-
BB/PDGFRβ regulates maturation of newly formed blood vessels via recruitment of PCs 
and SMCs
213,247,248
.  
Notably, a subpopulation of PDGFRα-expressing bipotential AC progenitors that can 
differentiate into both white and brown ACs under appropriate stimuli has recently been 
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identified
249
. Detailed molecular studies including identification and origin of the ligand are 
required to further elucidate the mechanism underlying PDGFRα-mediated determination 
of preadipocyte fate.  
1.2.5 Reciprocal interaction between adipose tissue and the vasculature 
The adipose tissue, both WAT and BAT, is highly vascularized. Each AC is surrounded by 
a blood vessel, reflecting the close functional relationship between adipose tissue and the 
vasculature
41,63,202,205,212,250,251
. Maintaining appropriate blood flow and supply with 
endothelial-derived factors is crucial for adipose tissue expansion, remodeling and 
metabolic functions
202,212,250
. Similarly, the adipose tissue produces and releases a myriad of 
vasoactive adipokines that affect angiogenesis and vascular functions in an endocrine and 
paracrine manner. Consequently, disruptions in the secretion of these molecules is critically 
involved in linking obesity to endothelial dysfunction
63,202,212,250
. Endothelial dysfunction is 
defined as increased vasoconstriction and impaired vasodilatation and is associated with a 
number of pathological conditions such as hypertension, atherosclerosis, adipose tissue 
inflammation and insulin resistance
250,252
.  
The critical role of microvessel growth in the development of adipose tissue is reflected by 
the spatio-temporal link between adipogenesis and angiogenesis during embryonic 
development. In early adipose tissue organogenesis, fat cell clusters, so-called “primitive 
organs” develop through formation of vascular structures and subsequent migration of 
preadipocytes into fat cell clusters. During the fetal stage, size and number of these 
primitive fat organs increase
253–256
. Studies suggest that plasminogen activator inhibitor-1 
coordinates adipogenesis and angiogenesis in the formation of primitive fat organs by 
regulating migration of preadipocytes and ECs
257
. There are indications that ACs and ECs 
may share a common progenitor with potential to differentiate into either lineage depending 
on external stimuli thus strengthening the concept of a close interrelationship of these two 
cell types
258
. Furthermore, a recent study revealed a perivascular origin of preadipocytes. 
Both stromal vascular cells as well as a subset of capillary ECs was found to express 
Zfp423, a gene regulating preadipocyte determination
212,255,258–260
. However, a recent study 
challenges the hypothesis of a potential pericytal or endothelial origin of AC precursor cells 
supporting the view that a mesenchymal Pref-1 positive progenitor gives rise to ACs
261
.  
Adipose tissue growth and remodeling does not only occur during early development but 
also plays a role during the postnatal period and adulthood. Adipose tissue is highly plastic, 
experiencing continuous expansion and shrinkage throughout the lifetime depending on 
nutritional status of an individual
202,205,212
. The adipose vasculature is critically involved in 
adipose tissue homeostasis by exerting a number of functions. Blood vessels transport 
albumin-bound FFAs as well as lipoproteins containing TGs and cholesterol
262
. Moreover, 
the vasculature supplies oxygen and nutrients, but also removes waste products. These 
functions are especially important in metabolically highly active BAT
63
. Moreover, the 
vasculature delivers plasma containing growth factors, hormones, immune cells and 
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cytokines to the adipose tissue and thereby contributes to maintaining AC survival and 
function. Additionally, activated ECs also produce a number of factors which modulate 
adipose tissue growth and homeostasis in a paracrine manner
63,212
. In terms of adipose 
tissue expansion, blood vessels play a dual role. Firstly, the vasculature supplies circulating 
stem cells with adipogenic potential, such as bone-marrow derived stem cells and 
mesenchymal stem cells originating from other tissues
63,212
. Secondly, recent studies 
demonstrated that murine and human adipose progenitor cells reside in the mural 
compartment of the adipose vasculature
259,260,263
. Owing to microvessel fenestration, the 
vasculature is also involved in mediating systemic functions of adipose tissue via secreted 
adipokines such as adiponectin or leptin which act on the hypothalamus
63,264,265
. It is 
noteworthy that AC-derived factors have been well studied regarding their role in 
promoting angiogenesis. However, to date, the molecular mechanisms underlying EC-
mediated modulation of adipocyte growth and function remain poorly understood.   
1.2.6 Targeting the adipose vasculature modulates adipose tissue function 
and whole body metabolism 
Due to the fact that adipose tissue growth is critically dependent on angiogenesis, anti-
angiogenic therapy appears to be a promising approach to prevent or reverse adipose tissue 
overgrowth, obesity and related metabolic disorders. However, both inhibition and 
stimulation of angiogenesis has been reported to contribute to a leaner phenotype and 
improved metabolic profile in several pre-clinical mouse models. These findings are based 
on both pharmacological interventions as well as genetic VEGF gain-of-function and loss-
of function approaches
145,205,251,266–269
. The metabolic status of adipose tissue appears to be 
a critical determinant whether positive or negative modulation of angiogenesis should be 
achieved to treat obesity. In metabolically quiescent WAT, angiogenesis may promote 
adipogenesis and energy deposition whereas microvessel growth in metabolically active 
BAT facilitates energy expenditure
63
. It has been established that dysfunction of adipose 
tissue rather than its absolute mass determines metabolic health
3,4
. Chronic deprivation of 
oxygen through anti-angiogenic therapy may have detrimental system effects on metabolic 
health as the dysfunctional adipose tissue may cause ectopic lipid deposition. Paradoxically, 
hypoxia-induced adipocyte death could counteract adipose tissue expansion and thereby 
have beneficial effects. Interestingly, the effects of vascularization on obesity and metabolic 
health seem to be stage-dependent. Inhibiting angiogenesis at early stages of obesity 
development aggravates adipose tissue inflammation and insulin resistance, potentially by 
shifting adipokine production towards a diabetogenic profile. Thereby, a reduction of 
adipose vascularization at early stages of obesity appears to have detrimental local and 
systemic effects
251,266,267
. However, suppression of angiogenesis when obesity is already 
established appears to reverse metabolic defects such as glucose intolerance or insulin 
resistance potentially by triggering apoptosis of malfunctioning adipocytes thereby 
inducing adipose tissue regression
251,266,267
. The underlying molecular mechanisms remain 
elusive and further detailed studies are required in order to define a promising therapeutic 
approach for the treatment of obesity by modulating the adipose vasculature.  
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2 AIMS OF THIS THESIS 
 
The aims of this thesis were to establish appropriate models to study adipose tissue 
angiogenesis and lymphangiogenesis and to use these models to investigate WAT browning 
as well as to study the effects of targeting the adipose vasculature on obesity and metabolism.  
 In paper I we aimed at establishing a non-invasive, physiologically relevant model of 
BAT activation and WAT browning. We intended to optimize available methodology 
to study adipose tissue and adipose vasculature morphologically. Furthermore, we 
provide approaches to study the physiological outcome of cold-induced alterations in 
WAT and BAT.  
 The aim of paper II was to evaluate the effect of ageing on the adipose vasculature 
and AC function. We investigated the relationship between blood vessels in various 
adipose depots and insulin sensitivity. We further studied the systemic effect of 
targeting the adipose vasculature with anti-angiogenic agents in both lean and obese 
mice.  
 In paper III we investigated the reciprocal crosstalk between ACs and vascular ECs. 
A variety of factors secreted by the adipose tissue that modulate vessel growth and 
function via paracrine signaling has been described in the literature. However, our 
study aimed at identifying EC-derived factors that might modulate adipogenesis and 
AC function.  
 The aim of paper IV was to develop an in vivo model that would allow the 
investigators to study the lymphangiogenic potential of various growth factors and 
molecules. This model could be used in future studies to define a potential role of 
lymphatic vessels in modulating adipose tissue and metabolism. 
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3 METHODS 
In the following, the most important methods used in the constituent papers are described in 
detail. 
3.1 MOUSE COLD ADAPTATION ASSAY 
In this assay, the effect of cold exposure on UCP1-dependent NST as well as transformation 
of WAT to beige adipose tissue can be studied. The control group of mice is maintained at 
their thermoneutral temperature around 30 °C. At this temperature, mice do not require any 
thermoregulatory activity in order to sustain their body temperature. Another group of 
animals is first adapted at moderate cold (18 °C) for a minimum of one week. For wild type 
mice, one week of adaptation is sufficient to activate their NST capacity so that they will 
tolerate subsequent cold exposure. Certain genetically modified strains, such as UCP1-/- mice 
however, require longer adaptation for up to three weeks. After adaptation at moderate 
temperature, mice can be transferred to the cold (4 °C). For this assay as for all experiments 
involving animals, it is critical to adhere to ethical regulations and guidelines and humane 
considerations are required in order to prevent unnecessary suffering of the mice. 
3.2 INDIRECT CALORIMETRY 
3.2.1 Measurement of basal metabolic rate  
Mice are placed into a metabolic chamber with free access to food and water and a regular 
12h-light:12h-dark cycle. The temperature of the metabolic cage is adjusted to the desired 
value. During the following 24 hrs, oxygen (O2) consumption and carbon dioxide (CO2) 
production are measured. The obtained values can be used to determine whole body energy 
expenditure and the Respiratory Exchange Ratio (RER). The RER is the ratio between CO2 
production and O2 consumption, which provides information about the primary source of 
energy for the mice. A RER of 0.7 implies that fat is primarily used as an energy source while 
RER ≥ 1 indicates that carbohydrates serve as main fuel. A mix of fat and carbohydrates is 
reflected by a RER of 0.85. 
3.2.2 Measurement of NE-induced NST 
Mice are anesthetized with pentobarbital to avoid muscle movement during this assay and 
placed in a metabolic chamber with an internal temperature of 33 °C to maintain mouse body 
temperature. For approximately 30 min, O2 consumption and CO2 production are measured 
continuously. After a stable baseline is obtained, 1 mg/kg NE is injected subcutaneously at 
the dorsal midline of the mouse and the respiratory parameters are measured for about 
90 min. This assay measures NST and thereby provides information about BAT activation 
and UCP1 activity. 
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3.3 INTRAPERITONEAL INSULIN TOLERANCE TEST (IPITT) 
Prior to this physiological assessment of insulin sensitivity, mice are fasted for 4 – 5 hrs with 
free access to drinking water. At the end of the fasting period, the baseline blood glucose 
level (t=0) is assessed with a glucometer. For this purpose, the mouse tail vein is punctured 
with a sterile needle and a drop of blood is applied to a glucose test strip. For the IPITT, 0.5 
Units of Insulin are injected intraperitoneally into the mouse. The dose of insulin depends on 
the mouse strain and potential treatment that the animal has undergone previously which 
might render the mouse more or less sensitive to insulin. It is therefore critical to establish the 
proper insulin dose in a pilot experiment in order to prevent the mice from becoming severely 
hypoglycemic during the IPITT. A drop of blood is collected 15, 30, 60 and 120 min post 
insulin injection and the respective blood glucose levels are determined using a glucometer. 
After completing this experiment, mice are returned to their home cage with free access to 
food and water and monitored closely until they have recovered. 
3.4 QUANTITATIVE DETECTION OF BLOOD LIPID COMPONENTS, GLUCOSE 
AND INSULIN 
Immediately after sacrificing the mice with an overdose of CO2, blood is collected by cardiac 
puncture and serum is prepared. Serum levels of cholesterol, glucose, glycerol, non-esterified 
free fatty acids (NEFA) and TGs were quantitatively assessed using colorimetric assays. 
Circulating insulin was detected in mouse serum and quantified using a sensitive Mouse 
Insulin ELISA Kit. To determine fasting glucose and insulin levels, mice were fasted for 4 – 
5 hrs prior to euthanasia. 
3.5 HISTOLOGY, WHOLE MOUNT ANTIBODY STAINING AND 
IMMUNOHISTOCHEMISTRY 
At the experimental endpoint, mice were sacrificed and adipose tissues as well as other 
organs were dissected and collected immediately. Tissues were fixed in 4 % paraform-
aldehyde (PFA) overnight and then transferred to phosphate-buffered saline (PBS). A portion 
of the tissue was embedded in paraffin for microtome sectioning and immunohistochemistry 
staining while another portion was used for whole mount antibody staining.  
For whole mount staining, sections of about 1 mm thickness were prepared by carefully 
cutting the tissue with a sharp scalpel blade. The tissue was digested with Proteinase K 
(20 mg/ml) and permeabilized with methanol. After thoroughly rinsing, unspecific binding 
sites were blocked with 3% milk in PBST prior to incubation with a primary antibody 
overnight. The following day, the tissue was washed and incubated with an appropriate 
fluorescence-linked secondary antibody. It is possible to use a combination of different 
antibodies generated in different species to obtain double or triple staining of several cellular 
components. Positive signals were detected using confocal microscopy. 
For immunohistochemistry, 5 µm thick sections of paraffin-embedded tissue were prepared 
using a microtome. Tissue sections were rehydrated in an ethanol/water series. After antigen 
unmasking, unspecific binding sites were blocked with 5% normal goat serum and sections 
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were incubated with primary antibodies at appropriate dilutions in a humid chamber 
overnight. The following day, sections were washed and incubated with suitable secondary 
antibodies. The tissue was then mounted in mounting medium containing DAPI to visualize 
cell nuclei and the sections were analyzed using a fluorescence microscope. 
3.6 MICROSCOPY 
Imaging was done using fluorescence or confocal microscopy. Fluorescence microscopy 
allows the analysis of thin tissue sections e.g. to detect co-localization of certain intracellular 
markers. Confocal microscopy permits the analysis of whole mount tissue by subsequently 
scanning several layers of defined thickness and at defined step size. The stack of images is 
then merged into a sharp three dimensional image. Thereby, structure and organization of the 
vasculature can be studied in great detail. The images obtained by fluorescence or confocal 
microscopy were analyzed in a qualitative and quantitative manner using the software Adobe 
Photoshop Creative Suite 5.  
3.7 RNA EXTRACTION AND QUANTITATIVE REAL TIME PCR (QRT-PCR) 
Immediately after euthanasia, adipose tissues were dissected and snap frozen in liquid 
nitrogen. For RNA isolation, WAT and BAT were homogenized and total RNA was isolated 
using an RNA isolation kit. Approximately 1.5 µg total RNA were reversely transcribed and 
the cDNA was used for subsequent qRT-PCR. Each 20 µl reaction contained 1 µl cDNA, 
10 µl SYBR Green reagent, and 150 nM forward and reverse primers, respectively. The 
protocol contained 40 cycles with each cycle comprising denaturation for 15 s at 95 °C, 
annealing for 1 min at 60 °C, and extension for 1 min at 72 °C. Threshold cycle (Ct) values 
were determined for all samples. The housekeeping gene actin was used as an internal control 
and all Ct values of the target genes were normalized to the Ct value of actin. The 2-ΔΔCt 
method was used to calculate the relative abundance of transcripts. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I: COLD-INDUCED ACTIVATION OF BROWN ADIPOSE TISSUE 
AND ADIPOSE ANGIOGENESIS IN MICE 
Several research groups have shown that cold exposure activates rodent BAT and induces a 
transformation of scWAT to a beige/BRITE phenotype via sympathetic activation
101,103,145,270
. 
Adipose tissue plasticity is associated with vascular alterations due to a switch in the balance 
between pro- and anti-angiogenic factor expression
202,212
. Along with morphological changes, 
functional alterations of the adipose tissue can be observed during cold adaptation and may 
result in modulation of whole-body energy homeostasis. In this paper, we describe a mouse 
model to systematically study cold-induced adipose tissue angiogenesis and BAT activation 
in a non-invasive manner. This protocol evaluates step by step the investigation of WAT, 
BAT and the adipose vasculature on a morphological level and provides tools to study the 
functional consequences of temperature-induced modulation of the adipose tissue phenotype. 
Commonly encountered problems are addressed in a separate troubleshooting section. 
In the model described in this protocol, mice are divided into two groups. One group of mice 
is maintained at their thermoneutral temperature of 30 °C while the second group of mice is 
adapted to a low ambient temperature. For this purpose, mice are initially acclimatized at 
moderate cold (18 °C) for one week before transition to 4 °C. Both groups should be exposed 
to the respective temperature for the same amount of time to allow for comparable results of 
the experiment. At the experimental endpoint, several parameters can be studied including 
metabolic rate, non-shivering thermogenic capacity, macroscopic and microscopic adipose 
tissue morphology as well as gene expression. Depending on the parameter of interest, the 
duration of this experiment should be adjusted. The cold-induced angiogenic response as well 
as BAT activation and scWAT browning are already evident after a few days of exposure. 
Prolonged exposure may further enhance the observed phenotype. When studying gene 
expression, it is recommended to study differential gene regulation both at an early and a late 
time point. Some genes may only be transiently upregulated; they may be induced after acute 
cold exposure but return to a basal level after prolonged, chronic exposure. Nevertheless, this 
model provides a tool to unravel the molecular mechanisms involved in microvessel growth. 
To study the effects of cold exposure on whole body energy homeostasis, we describe 
measurement of basal metabolic rate as well as UCP1-dependent NST. Basal metabolic rate 
is typically measured in non-sedated mice over a time period of 24-72 hrs. During the 
measurement, mice are maintained in their home cage which is placed inside a metabolic 
chamber with a fixed temperature, a 12h-light:12h-dark cycle and free access to food and 
water. To determine adaptive thermogenesis, mice are anesthetized to prevent muscle 
movement which may alter the results of this measurement and lead to high variability 
between individual mice. After obtaining a stable baseline, NST is stimulated by injection of 
NE and a rapid increase in O2 consumption and CO2 production can be observed. The 
magnitude of the response varies depending on BAT amount and activation status and allows 
conclusions regarding the animal’s NST capacity. Typically, in cold-exposed wild type mice, 
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the observed response to NE injection is significantly increased compared to mice maintained 
under thermoneutral conditions. As mice are anesthetized during this procedure, the ambient 
temperature in the metabolic chamber is to be set to 33 °C to prevent hypothermia. 
Furthermore, if performing this experiment at temperatures below the thermoneutral zone, 
BAT and NST may already be activated prior to NE-injection leading to inaccurate results
100
. 
In this protocol, we further describe different staining methods to histologically analyze 
adipose tissues. To obtain information regarding the three-dimensional structure and integrity 
of the adipose vasculature, whole mount staining and subsequent confocal imaging provide 
powerful tools. In order to investigate intracellular components such as mitochondria or to 
study the vascular density in relation to the number of ACs, immunohistochemistry on 
paraffin or cryostat sections is preferable.  
The protocol described here can be employed using mouse strains of different genetic 
backgrounds. It is highly recommended to modify the protocol according to the mouse strain 
that is used. When using animals with genetic deletions of thermogenesis-related genes such 
as UCP1 knockout mice, acclimation time has to be prolonged to three weeks to prevent 
death of the animals. Additionally, this model can be used to investigate the effect of existing 
or potential anti-obesity or anti-diabetic drugs in combination with cold exposure. A 
combination-based approach may have beneficial additive or synergistic effects on body 
weight reduction and improvement of metabolic health. Using this model, we studied the 
mechanisms underlying VEGF-related angiogenesis during browning of WAT (Paper III).  
4.2 PAPER II: MODULATION OF AGE-RELATED INSULIN SENSITIVITY BY 
VEGF-DEPENDENT VASCULAR PLASTICITY IN ADIPOSE TISSUES 
Obesity-related metabolic disorders account for the most common causes of death globally 
and pose a large burden on health care systems in various countries. Interestingly, the risk to 
develop T2D increases dramatically when individuals reach an age of 40 years. According to 
the Centre of Disease Control and Prevention, nearly two thirds of individuals diagnosed with 
T2D in 2011 were between 40 – 64 years old271. Although it is known that both ageing and 
obesity constitute major risk factors for the development of this disease, it remains enigmatic 
why the incidence of T2D dramatically increases in middle-aged subjects. There is evidence 
that ROS-induced mitochondrial damage is associated with age-related muscle insulin 
resistance
272
. Although little is known regarding the effect of ageing on the adipose 
vasculature in vivo, it has been reported that vascularization and angiogenesis are impaired in 
the adipose tissue of older mice
42,273
. 
In this paper, we provide evidence that alterations in the adipose vasculature and Vegf 
expression during ageing, correlate with the risk of developing T2D. In the first part of our 
study, we investigated age-related alterations of the adipose vasculature as well as AC 
morphology and functions. One mouse day roughly corresponds to 50 human days, assuming 
a lifespan of 2 years for mice and 100 years for humans, respectively. For this ageing-study, 
we included C57Bl/6 mice of ages 1, 4, 10, 12, and 16 months which corresponds to 4-, 17-, 
42-, 50-, and 70-year old humans. In our study, average AC diameters in WAT gradually 
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increased from 1 mo to 10 mo of age where they reached a maximum of 106 (± 2.7) μm in 
scWAT and 116 (± 0.6) μm in epiWAT. The observed AC hypertrophy correlated with an 
increase in body weight and BMI with increasing age. When mice exceeded the age of 
10 mo, average AC size decreased while body weight and BMI stabilized. We also found that 
blood vessel density in several WAT depots of healthy, lean mice varied markedly over the 
mouse life span. Microvessel density was highest in the youngest mice (1 mo-old) and 
steadily decreased reaching a minimum in middle-aged animals. In accordance with these 
findings, VEGF protein levels in WAT were lowest at the age of 10 mo. After 10 mo of age, 
WAT microvessel density gradually increased. Similar alterations in vessel density and AC 
diameter were observed in interscapular BAT (intBAT); however, these effects were more 
subtle compared to WAT. Interestingly, total intBAT mass increased with age and the tissue 
mass in 16-mo old mice was approximately two times higher compared to the youngest age 
group in our study. However, despite this increase in total mass, UCP1 mRNA and protein 
levels were markedly reduced at 12 and 16 mo compared to younger mice at 4 mo of age. 
This indicates that BAT activation was lower in older mice. To gain further molecular insight 
into the mechanisms underlying age-related alterations of the adipose vasculature, we studied 
the expression of Vegfr1 and Vegfr2 in WAT and BAT. We found that Vegfr1 expression was 
highest at 10 mo of age. This finding is in accordance with the hypothesis that this receptor 
mainly functions as a decoy receptor for VEGFA and acts as a negative regulator of 
angiogenesis. On the contrary, Vegfr2 expression was highest in the youngest animals and 
decreased with age reconciling with its role as a transducer of VEGF-induced angiogenesis.  
Next, we studied age-related changes in AC functions such as lipolysis and insulin sensitivity 
by analyzing serum levels of several blood lipids as well as fasting glucose and insulin levels. 
While no overwhelming age-related changes in serum TGs, NEFA, glycerol, cholesterol or 
fasting glucose could be detected, circulating insulin was markedly increased with age, 
resulting in substantially reduced insulin sensitivity in older animals. At the age of 10 mo, 
mice exhibited a strong elevation in circulating insulin levels and greatly increased HOMA-
IR values compared to younger animals indicating insulin resistance. This onset of insulin 
resistance was negatively correlated with adipose vascularization as vascular density in both 
epiWAT and scWAT was lower at this age compared to all other age groups included in this 
study. We concluded that VEGF modulates angiogenesis in the adipose tissue and that lower 
vascular density is associated with an increased risk of developing insulin resistance and 
T2D. To validate this hypothesis and to further study the role of VEGF signaling in age-
related development of insulin resistance and T2D, we treated lean, healthy mice of 1-, 7- and 
15-mo of age with specific anti-VEGF and anti-VEGFR2 neutralizing antibodies. 
Paradoxically, treatment with anti-VEGF antibody decreased adipose vascular density while 
improving insulin sensitivity via significantly lowering serum glucose levels in all studied 
age groups. The magnitude of this effect however varied greatly with age and middle-aged 
animals exhibited a rather moderate response as compared to younger and older mice. To get 
further insight into the mechanism of anti-VEGF-induced decrease of blood glucose, we 
performed an IPITT on vehicle- and anti-VEGF-treated animals of different age. In young 
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and old mice, glucose clearance following administration of 0.5 Units insulin per kilogram 
body weight was significantly accelerated in mice treated with anti-VEGF. In middle-aged 
mice, however, glucose clearance was not significantly altered after anti-VEGF treatment. 
These findings validate that middle-aged mice were less sensitive to anti-VEGF therapy 
compared to other age populations. The observation that anti-VEGF-mediated vascular 
reduction improved insulin sensitivity was unexpected and further studies are required to 
fully unravel the underlying complex mechanism.  
To investigate whether anti-VEGF therapy might have beneficial effects on insulin sensitivity 
in a clinically relevant model of DIO, mice were fed a high fat diet to induce adipose 
hypertrophy and insulin resistance. Treatment of these animals with an anti-VEGF antibody 
expectedly reduced adipose vascular density. As seen in lean, healthy animals, VEGF-
blockade could significantly improve DIO-associated insulin resistance as well as glucose 
clearance in an IPITT. In this model, anti-VEGF therapy markedly reduced body weight, 
BMI, as well as total mass of scWAT, epiWAT and intBAT. The average AC diameter in all 
studied adipose depots decreased significantly after anti-VEGF treatment. In BAT, anti-
VEGF therapy reduced the amount of lipid deposition and increased mitochondrial content. 
These findings suggest that anti-VEGF agents might offer a novel opportunity to improve 
insulin sensitivity in obese patients. Further studies using a mouse model with fully 
developed T2D will be necessary to determine whether anti-VEGF therapy is effective under 
established disease conditions. 
Taken together, our findings further demonstrate that adipose vasculatures show differential 
responses to anti-VEGF treatment in various age populations. This phenomenon might have 
therapeutic implications for treatment of obesity and diabetes with anti-VEGF-based anti-
angiogenic drugs. Currently, several anti-VEGF based drugs are used in clinical settings in 
the treatment of cancer patients as well as in ophthalmological disease therapy
274,275
.  
4.3 PAPER III: ENDOTHELIAL PDGF-CC MEDIATES VEGF-ANGIOGENESIS-
DEPENDENT THERMOGENESIS IN BROWNING FAT 
The adipose microenvironment contains various cell types such as AC, vascular ECs, stromal 
cells and inflammatory macrophages
63,202
. A crosstalk between these distinct cell populations 
coordinates adipose tissue growth, expansion and remodeling. ACs might communicate with 
ECs in a paracrine manner by producing a myriad of cytokines and factors
63,212
. It is likely 
that ECs modulate AC functions via soluble or membrane-bound factors; however, little is 
known about this potential crosstalk. In this paper, we studied the role of angiogenesis in 
modulating AC functions. We show that ECs are critically involved in WAT browning 
following adrenergic activation. Our findings indicate that EC-derived PDGFC induces 
differentiation of progenitors into ACs. Pharmaceutical blockade of PDGFRα as well as 
deletion of the Pdgfc gene could greatly abolish the paracrine regulatory effect and markedly 
reduce WAT browning.  
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It has previously been shown that PDGFRα+ cells constitute bi-potential AC progenitors that 
can differentiate into both WAT and BAT ACs in vitro
2,249
. However, the identity and source 
of the ligand have not been described yet.  
WAT browning mediated by adrenergic activation is well established. In our study, 
administration of the specific β3-adrenergic agonist CL induced a strong angiogenic response 
in gonadal WAT (gWAT) of mice. We detected increased vessel density in this adipose depot 
already after 2 days of treatment and a 3-fold increase was seen at day 10 of CL treatment. 
We found that Vegf expression was markedly increased in the adipocyte fraction but not in 
the stromal vascular fraction (SVF) of gWAT upon CL treatment. Angiogenic effects were 
also observed in other WAT depots as well as in intBAT. A similar angiogenic response was 
observed in scWAT and BAT of cold-exposed mice while the increase in vascular density in 
gWAT was only moderate. Local adenoviral delivery of VEGF (AdVEGF) to mice induced 
Vegf expression, angiogenesis and browning in gWAT. However, thermogenic capacity of 
these mice remained unaltered leading to the conclusion that whole body energy homeostasis 
is not significantly affected by gWAT browning. This finding implies WAT depot-specific 
differences regarding the contribution to whole body energy expenditure. 
Additionally, CL treatment induced browning of gWAT and scWAT and markedly increases 
Ucp1 expression levels of these depots. In cold-exposed animals, only scWAT exhibited a 
browning phenotype. Interestingly, UCP1-deficient mice showed a VEGF-dependent 
angiogenic response as well as WAT browning while NST was abolished in these animals. 
These findings suggest that CL-mediated adipose angiogenesis is UCP1-independent and 
suggest a hypoxia-independent mechanism of Vegf upregulation since this growth factor is 
highly expressed upon adrenergic stimulation even in the absence of BAT or beige 
thermogenesis. There is strong evidence from various studies that PGC1α is involved in 
hypoxia-independent upregulation of Vegf expression
145,276
. To further delineate the 
mechanism underlying CL-induced adipose angiogenesis, we analyzed expression levels of 
Vegfr1 and Vegfr2 in the CD31
+
 EC fraction. We found that both receptors showed marked 
upregulation after CL-treatment. Blockade of VEGFR2- but not VEGFR1-mediated signaling 
with specific antibodies completely abolished gWAT angiogenesis after adrenergic 
activation. Additionally, browning of WAT, UCP1 expression and NST were strongly 
suppressed when blocking this receptor indicating a critical role of VEGFR2-VEGF-signaling 
in this process. This observation was strengthened using a genetic model with endothelial 
deletion of VEGFR2. These findings pointed at a paracrine regulation of AC functions by 
VEGFR2-activated ECs. As VEGFR2 expression is largely restricted to ECs, our findings 
highlight the role of the vasculature in WAT browning. 
To define potential VEGF-induced EC-derived factors involved in the paracrine modulation 
of AC function, we performed genome-wide gene expression analysis. We found that 
PDGFC was among the most upregulated growth factors in the SVF of CL-treated gWAT. 
Additionally, Pdgfc was strongly induced in the SVF of gWAT upon AdVEGF transduction 
suggesting that this factor indeed plays a role in gWAT browning. Expression of Pdgfc was 
  33 
restricted to CD31
+
 ECs and ablated in VEGFR2-deficient mice indicating that VEGFR2 
signaling is required for CL-induced Pdgfc expression in ECs. In mice deficient for PDGFC, 
CL treatment induced an angiogenic response in the adipose tissue; however, browning and 
Ucp1 expression were strongly suppressed. This effect could be rescued by local delivery of 
AdPDGFC to gWAT and scWAT of these mice. A pharmacological approach using specific 
antibodies against both PDGFRα and PDGFRβ suppressed CL-induced browning of WAT 
but not angiogenesis. The suppressive effect was more pronounced when blocking PDGFRα. 
This observation was verified in a physiologically relevant model by treating cold-exposed 
mice with these specific antibodies. Interestingly, only PDGFRα blockade led to a significant 
reduction of NST capacity. To further delineate the mechanism underlying PDGFC-regulated 
WAT browning, we studied the identity of PDGFRα+ cells in the adipose tissue. Interestingly, 
PDGFRα was expressed exclusively on adipose stromal cells and expression could be 
increased by CL-treatment. We therefore hypothesized that this population of CD34
+
, Sca1
+
 
and PDGFRα+ cells constitutes a pool of adipose progenitor cells that can differentiate into 
UCP1-expressing beige ACs under appropriate stimuli such as treatment with PDGFC. Taken 
together, we concluded that endothelial PDGFC contributes to regulating the paracrine 
activation of PDGFRα+ beige AC precursor cells via VEGF-VEGFR2 signaling. 
4.4 PAPER IV: MOUSE CORNEAL LYMPHANGIOGENESIS MODEL 
While hemangiogenesis in the adipose tissue is being extensively studied, knowledge about 
adipose lymphangiogenesis specifically in respect to WAT browning is scarce. Several in 
vitro assays are established to study LEC proliferation or migration; however, lymphatic 
vessel maintenance requires stabilization and remodeling of the vessels which can only be 
investigated in vivo in the context of a functional lymphatic network. Others have described a 
mouse cornea suture model in which lymphangiogenesis is induced by inflammation. In this 
model, a suture is placed in the epithelial layer of the mouse cornea resulting in an 
inflammatory response. However, in this setting, a number of cytokines and factors 
concertedly induce lymphangiogenesis and it is not possible to delineate the effect of a single, 
specific factor. While this model is suitable for testing the effect of potential novel drugs on 
inhibiting lymphangiogenesis independent of targeting a particular factor, it cannot be used to 
study the role of a specific cytokine in inducing lymphatic vessel growth.  
In this paper, we present an in vivo model to study the lymphangiogenic potential of specific 
cytokines and other factors in the mouse cornea. This model also provides an opportunity to 
address the mechanisms underlying remodeling of lymph vessels as well as functional aspects 
of the lymphatic network. As opposed to blood vessels, lymphatic vessels are not perfused 
with blood and consequently remain invisible to the naked eye. To visualize lymphatics, 
specific markers including lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), 
VEGFR3 or podoplanin are commonly used. The major drawback of immunohistochemical 
staining of lymphatic vessels is that the markers do not distinguish between pre-existing and 
newly formed lymph vessels. Moreover, some markers are not suitable to use for detection of 
lymphatics in all tissues. The marker LYVE-1 for instance does not provide reliable results 
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when used in the adipose tissue. In addition to lymphatics, LYVE-1 also stains other 
components such as adipose macrophages. In our cornea model, we take advantage of the 
avascular nature of the cornea under physiological conditions. Consequently, all lymphatic 
vessels that are detected in this assay constitute newly formed vessels and therefore this 
model allows us to study lymphangiogenesis in a quantitative manner.  
The procedure consists of four steps: (1) micropellet preparation, (2) corneal implantation, (3) 
immunohistochemistry and (4) data analysis. For this purpose, uniform slow-release 
micropellets are prepared containing equal amounts of factors to ensure reproducibility and 
robustness of this assay. The pellet is then surgically implanted in the mouse cornea by 
creating a micropocket on one eye of the animal. After a defined period of time, animals are 
euthanized and the cornea is carefully dissected. Whole mount immunohistological staining 
can be performed using lymphatic markers such as LYVE-1. Depending on the experimental 
question, double or triple staining with other specific antibodies (e.g. anti-CD31) can be 
performed. Confocal images can be acquired and the average lymphatic vessel area can be 
quantified.  
In addition to studying the potential lymphangiogenic effect of a single factor or several 
factors in combination, this model can also be used to test potential novel drugs that might 
inhibit lymphangiogenesis or modulate remodeling and function of lymphatic vessels. 
Dysfunctional lymph vessels lead to the formation of lymphedema due to inadequate 
drainage. In this condition, excessive amounts of lymph accumulate in the interstitial space. 
In severe cases, persistent lymphedema will result in proliferation of fibrous tissue and may 
eventually lead to a condition termed Massive Localized Lymphedema which is often 
observed in morbidly obese patients
277–279
. Lymphedema also constitutes a problem in cancer 
treatment, particularly in breast cancer patients following partial or total mastectomy
280
. 
Delivery of lymphangiogenic factors might restore lymph vessel structure and function and 
thereby offer an attractive potential novel treatment option for patients with lymphatic 
dysfunction. On the other hand, inhibiting lymphangiogenesis may provide a powerful 
approach to prevent metastatic spreading of disseminated tumor cells from the primary tumor 
in cancer patients.  
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5 CONCLUSIONS AND FUTURE DIRECTIONS 
This thesis describes the use of several mouse models to study the role of angiogenesis in the 
context of obesity and related metabolic disorders such as T2D. We also study the 
mechanism of WAT browning and the potential role of the vasculature in this process. This 
work describes two different approaches to induce WAT browning and BAT activation, cold 
exposure and pharmacological adrenergic activation using the specific Adrb3 agonist CL. 
In Paper I, we describe a non-invasive, physiologically highly relevant model in which mice 
of different genetic backgrounds can be acclimated to cold ambient temperature. We describe 
various methods to study the effects of cold exposure on tissue morphology and composition 
as well as metabolic parameters such as whole body energy expenditure and NST-capacity. 
This model allows the investigator to combine cold exposure with drug treatment using small 
molecules, proteins or other compounds. It would be interesting to evaluate the effect of cold 
exposure in combination with currently used drugs for obesity or T2D therapy. As previous 
studies have shown that cold-induced WAT browning might be a beneficial approach for 
weight loss and improvement of metabolic health in healthy individuals, subpopulations with 
predisposition for arteriosclerosis appear to be at great risk for plaque instability due to cold-
induced lipolysis following this regimen
281
. The mechanism underlying these differential 
effects remain to be elucidated and it would be interesting whether combining cold exposure 
with cholesterol-lowering drugs might abolish this effect. Furthermore, our model allows 
identifying and studying novel molecular players regulating WAT browning and metabolic 
status of an individual. These molecules might constitute potential targets for the treatment of 
obesity and related disorders.  
Although this model provides an excellent opportunity to study adipose vasculature and 
metabolism in a non-invasive way, there are certain limitations and considerations that should 
be made to obtain reproducible, stable and scientifically meaningful results. A common 
disadvantage of general animal housing conditions with regard to metabolic studies is the fact 
that the ambient temperature of 22-23 ˚C is significantly lower than the animals’ 
thermoneutral temperature. Thus, mice are facing a temperature challenge resulting in BAT 
activation and increase in NST capacity, which can lead to a misinterpretation of metabolic 
measurements. Additionally, ambient temperature-induced alteration of NST may mask 
potential true changes in metabolic rate due to genetic alterations or drug treatments
100
. 
Therefore, including appropriate controls maintained at thermoneutral temperature is critical 
when performing metabolic studies. Furthermore, when measuring NST-capacity, NE-
injection itself induces a pharmacological, BAT-independent elevation of metabolism that 
may cause an overestimation of NST-capacity. To determine the true extent of adaptive NST, 
measurements obtained from the control group housed at thermoneutrality provide 
background values and can be used to normalize the data
100,282
. As prolonged housing at 
thermoneutrality markedly decreases UCP1 activity, measurements obtained from this control 
group cannot be attributed to adaptive NST and can be subtracted. Alternatively, UCP1-
ablated animals may be used as a control
100
. Another possibility to avoid overestimation of 
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adaptive thermogenesis due to a pharmacological response to NE injection may be the use of 
specific Adrb3 agonists such as CL as the receptors targeted by this compound show 
significantly higher expression in adipose tissue compared to other organs. However, specific 
agonists only target Adrb3 and neglect the contribution of β1- and α-adrenergic receptors 
which may be required for a full thermogenic response
100,283,284
.  
There are different ways of representing results of metabolic measurements; most frequently 
they are given per animal or normalized per kilogram bodyweight. However, when 
comparing lean versus obese animals, the body weight difference is largely due to excess 
lipid accumulation in obese animals rather than alterations in lean body mass. Lipid droplets 
do not contribute to the thermogenic effect and thereby normalization based on body weight 
may result in incorrectly low metabolic rates of obese animals compared to their lean 
counterparts
100
. Consequently, it is favorable to present the results per animal. In specific 
cases – such as when substantial differences in muscle mass between experimental groups are 
observed – normalization based on lean body mass may provide more accurate estimations of 
the metabolic rate
100
.    
A challenge when measuring whole body energy expenditure is to determine whether 
potential alterations are due to increased BAT activation or attributable to beige adipose 
tissue. This question may be addressed using rodent models in which BAT depots have been 
surgically removed. Alternatively, beige AC-specific induction of Ucp1 expression without 
affecting the expression level of this protein in classical BAT depots might help to further 
understand the contribution of beige adipose tissue to whole body energy expenditure
157
. To 
date, several studies indicate that beige ACs can compensate for the loss of brown fat 
cells
119,285
. Importantly, specific inhibition of scWAT browning and beige AC function leads 
to decreased thermogenic capacity and has detrimental consequences such as increased 
susceptibility to obesity, insulin resistance and further metabolic complications. These 
findings are rather unexpected as the total amount of UCP1 protein in beige cells is ten times 
lower compared to classical brown ACs
282
. Nevertheless, the results obtained from these 
studies highlight the importance of beige fat for whole body energy homeostasis 
159
. 
In Paper III, we describe drug-induced WAT browning using the adrenergic agonist CL. 
Treatment with this compound largely mimics cold-induced effects on AC morphology, 
blood vessel density and metabolism. However, as opposed to cold exposure, drug-mediated 
adrenergic stimulation induces browning not only in scWAT but also in gWAT which 
represents visceral adipose tissue. Interestingly, subcutaneous and visceral adipose depots 
appear to have opposing effects on metabolic health. While scWAT seems to play a 
protective role, visceral adipose tissue mass is positively correlated with metabolic 
dysfunction
286
. Detailed mechanistic studies using both the cold model as well as CL-induced 
browning might unravel the inherent differences between these two types of WAT. Here, we 
identify endothelial-derived PDGFC as a paracrine signaling molecule mediating the 
transformation of WAT to a BAT-like phenotype. This work shows how the vasculature can 
directly regulate WAT browning. These findings may lead to the identification of novel 
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options for the treatment of obesity. The PDGFC-induced effect on WAT browning is 
mediated via signaling through mainly PDGFRα, but PDGFRβ is also involved. Further 
studies are required to define whether additional EC-derived factors play a role in this 
process. Moreover, it would be interesting to study a potential correlation between Pdgfc 
expression and BAT or beige adipose tissue mass in human individuals as well as in lean 
versus obese patients. Notably, although treatment with CL provides promising results in 
numerous animal models, attempts to use this drug in clinical settings have not been 
successful to date. This illustrates that there are considerable discrepancies between animal 
studies and human settings that require further investigation. 
In Paper II we studied the role of ageing in relation to adipose tissue, in particular AC 
morphology and function as well as the effect on the adipose vasculature. Although it is well 
understood that both ageing and obesity constitute risk factors for the development of 
metabolic diseases such as T2D, the understanding of the role of the adipose vasculature is 
very limited. In this paper, we also describe a role of VEGF in modulating hyperglycemia 
and insulin sensitivity in mice. Decreased insulin sensitivity is a precondition of T2D and our 
findings show that it can be ameliorated by treatment with anti-VEGF agents. A number of 
anti-VEGF agents are currently used in clinical settings for the treatment of cancer 
patients
274,275
. Apart from the direct effect of VEGF inhibition on the tumor vasculature, 
additional mechanisms might contribute to the anti-tumor effect of this treatment. 
Interestingly, T2D and hyperglycemia constitute risk factors for several cancers such as 
colon, endometrial, kidney, pancreas, liver and breast cancer. Particularly in women, even 
moderately elevated blood glucose levels in non-diabetic individuals appear to increase the 
risk for developing cancer
287
. Cancer cells utilize glycolysis and subsequent lactate 
fermentation to obtain the energy required for their growth and proliferation (Warburg 
effect)
288,289
. It has been described that the glycolytic rate in cancer cells is up to 200 times 
higher compared to normal cells
288,290
. In most normal cells, pyruvate produced via 
cytoplasmic glycolysis is metabolized by mitochondrial oxidative phosphorylation generating 
36 ATP molecules per glucose molecule. As opposed to this more energy-efficient pathway, 
cancer cells only carry out the first step – aerobic glycolysis – yielding merely 2 ATP 
molecules. However, it enables the cells to rapidly convert nutrients into biomass which is 
advantageous for high growth rates and has been described not only in tumors but in various 
highly proliferative tissues
291–293
. Given both epidemiological and metabolic data, it is 
reasonable to speculate that lowering blood glucose levels may offer an attractive approach to 
inhibit tumor growth by depletion of their primary energy source
293
. Our study demonstrates 
that VEGF-blockade significantly decreases blood glucose levels. These findings may offer 
an additional mechanism underlying the effect of VEGF-agents in cancer therapy. However, 
further detailed studies are required to address this question. Long-term anti-VEGF-induced 
hypoglycemia might have adverse systemic effects that could potentially counteract patient 
health and survival. As a consequence of drug-mediated hypoglycemia, breakdown of 
adipose tissue and muscles in an attempt to restore glycaemia may occur leading to or 
aggravating cancer cachexia to a potentially fatal extent
293
. Furthermore, selective starvation 
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of cancer cells appears challenging and inducing hypoglycemia severe enough to cause the 
death of cancer cells would most likely have detrimental effects on other tissues within the 
body. While most organs are capable of adapting to ketogenic conditions, brain cells are 
highly glucose-dependent and may suffer severe damage following induced hypoglycemia 
which can lead to seizures and coma
116,294,295
. A potential approach to resolve this problem 
might be the local administration of glucose to the brain
296
. Comprehensive studies are 
required to further investigate this possibility.   
Whereas angiogenesis and the vasculature in adipose tissue are being extensively studied, 
only little is known regarding the role of lympatic vessels and lymphangiogenesis in this 
context. Particularly a potential involvement in WAT browning and modulation of whole 
body energy expenditure are of great interest. Lymphatic vessels as well as lymph nodes are 
in close spatial proximity of the adipose tissue, both subcutaneously as well as in the 
mesentery
297,298
. This close spatial proximity suggests that the lymphatics play a role in 
adipose metabolism. In fact, there is evidence for a reciprocal crosstalk between lymphatics 
and adipose tissue. Lymphatic vessels transport a variety of cargo such as immune cells, 
dietary lipids and proteins and may thereby – similar to blood vessels – play a critical role in 
maintaining functional adipose tissue
297,299,300
. Vice versa, when immune cell activation is 
required, increased lipolysis in the adipose tissue may provide energy to fuel the immune 
functions of the lymphatic system
297,298
. Animals with lymphatic deficiencies, such as mice 
with spontaneous heterogeneous mutations inactivating the gene encoding VEGFR3, exhibit 
adult-onset obesity and excessive depositions of subcutaneous adipose tissue. Additionally, 
disruption of lymphatic vessels induces AC differentiation-related complications resulting in 
hypertrophy and proliferation in the adipose tissue
301
. Although preliminary, there are 
indications that lymphangiogenesis is altered in the obese state
301,302
. Further evidence of the 
implication of lymphatic vessels has been obtained from mice with heterogeneous deletion of 
Prox1, a gene critically involved in LEC specification. Animals with only one allele of this 
gene exhibit disorganization and dysfunction of the lymphatic vasculature and develop adult 
onset obesity due to increased adipogenic differentiation
297,303,304
. Recent studies indicate that 
obesity predisposes individuals for lymphatic dysfunction and development of 
lymphedema
301,305
. Furthermore, it has been described that the function of the lymphatic 
system is compromised in a mouse model of high fat diet-induced obesity
301
. Further studies 
are warranted to elucidate this phenomenon and to unravel the mechanism underlying this 
observation. Our cornea lymphangiogenesis model described in Paper IV allows the 
investigator to study the angiogenic and lymphangiogenic potential of particular growth 
factors and molecules. This model could be used in the future to test the lymphangiogenic 
capacity of specific factors and adipokines that are differentially regulated upon cold 
exposure, drug-induced adrenergic activation and in obese or diabetic individuals. To study 
the lymphangiogenic capacity of adipocytes following adrenergic stimulation, cold-exposed 
or CL-treated adipose tissue could be implanted into the cornea using this model. For more 
detailed studies, that would allow to delineate which cells produce potentially 
lymphangiogenic factors, mature ACs and SVF could be separately implanted in the cornea.  
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